Nivolumab vs Pembrolizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT01673867 · Phase 3 · completed

This was a large randomized trial comparing nivolumab with active treatment, but it was open-label rather than double-blinded. The prespecified primary endpoint, overall survival, favored nivolumab and was statistically significant; however, the lack of blinding limits the strength of the evidence.

Next expected readout: November 2026 · NCT02955290 (registry estimate)

Reported efficacy

Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68) (met)

Result source: NCT01673867

Pembrolizumab

Marketed by Merck & Co.

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT02142738 · Phase 3 · completed

The trial randomized 305 participants to pembrolizumab or active platinum-based chemotherapy, but treatment was open-label rather than double-blinded. Its radiographically assessed primary endpoint, 6-month progression-free survival, was met: 62.1% with pembrolizumab versus 50.3% with chemotherapy, with p<0.001 and a hazard ratio of 0.50 (95% CI 0.37–0.68).

Next expected readout: November 2026 · NCT06545331 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) Rate at Month 6: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2) (met)

Result source: NCT02142738

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointNivolumabPembrolizumab
PFS, median12.1 vs 8.1+4 vs placebon 275NCT03117049
22 other results
8.8 vs 4.9+3.9 vs placebon 410NCT02578680
17 other results
OS, median12.2 vs 9.4vs Docetaxeln 292NCT01673867
20 other results
15.9 vs 11.3+4.6 vs placebon 278NCT02775435
15 other results
ORR61.5% vs 50.5%+11 vs placebon 275NCT03117049
19 other results
  • 19.5% vs 12.8% n 292 · Phase 3 · secondary NCT01673867
  • 20% vs 8.8% n 135 · Phase 3 · secondary NCT01642004
  • 36.4% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 27.5% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 26.2% vs 29.7% n 187 · Phase 3 · secondary NCT02477826
  • 37.9% vs 29.7% n 177 · Phase 3 · secondary NCT02477826
  • 52.3% vs 29.7% n 377 · Phase 3 · secondary NCT02477826
  • 38.1% vs 29.7% n 126 · Phase 3 · secondary NCT02477826
  • 67.6% vs 64.5% n 287 · Phase 3 · secondary NCT04026412
  • 72.2% vs 64.5% n 320 · Phase 3 · secondary NCT04026412
  • 61.3% vs 57.9% n 287 · Phase 3 · secondary NCT04026412
  • 63.1% vs 57.9% n 320 · Phase 3 · secondary NCT04026412
  • 26.1% vs 33.5% n 211 · Phase 3 · secondary NCT02041533
  • 50.6% vs 43% wk 64 · n 158 · Phase 2 · primary NCT04623775
  • 14.5% 3 mg/kg · n 117 · Phase 2 · primary NCT01721759
  • 17.1% 480mg Q4W · n 129 · Phase 2 · secondary NCT03090737
  • 15.4% 3 mg/kg · n 117 · Phase 2 · secondary NCT01721759
  • 32.3% n 288 · Phase 2 · secondary NCT02659059
  • 47.2% n 36 · Phase 2 · secondary NCT02659059
47.6% vs 18.9%+28.7 vs placebon 410NCT02578680
14 other results
  • 57.9% vs 38.4% n 278 · Phase 3 · secondary NCT02775435
  • 29% vs 27.1% n 245 · Phase 3 · secondary NCT03515837
  • 39.1% vs 32% wk 191 · n 299 · Phase 3 · secondary NCT02220894
  • 33.2% vs 28.9% wk 191 · n 413 · Phase 3 · secondary NCT02220894
  • 27.2% vs 26.5% wk 191 · n 637 · Phase 3 · secondary NCT02220894
  • 44.8% vs 27.8% n 154 · Phase 3 · secondary NCT02142738
  • 22.7% vs 14.3% n 185 · Phase 3 · secondary NCT03976375
  • 22.7% vs 12.5% n 185 · Phase 3 · secondary NCT03976375
  • 28.1% vs 7.1% n 114 · Phase 3 · secondary NCT02864394
  • 20.7% vs 5.7% n 213 · Phase 3 · secondary NCT02864394
  • 5.4% vs 11.1% n 37 · Phase 2 · primary NCT04165096
  • 71.4% n 112 · Phase 2 · primary NCT03631784
  • 75.5% n 102 · Phase 2 · primary NCT03631784
  • 22% vs 28% n 69 · Phase 2 · secondary NCT03971474
Duration of response, median11 vs 7+4 vs placebon 275NCT03117049
12 other results
11.2 vs 7.8+3.4 vs placebon 195NCT02578680
8 other results

PFS, median

Nivolumab
12.1 vs 8.1+4 vs placebon 275NCT03117049
22 other results
Pembrolizumab
8.8 vs 4.9+3.9 vs placebon 410NCT02578680
17 other results

OS, median

Nivolumab
12.2 vs 9.4vs Docetaxeln 292NCT01673867
20 other results
Pembrolizumab
15.9 vs 11.3+4.6 vs placebon 278NCT02775435
15 other results

ORR

Nivolumab
61.5% vs 50.5%+11 vs placebon 275NCT03117049
19 other results
  • 19.5% vs 12.8% n 292 · Phase 3 · secondary NCT01673867
  • 20% vs 8.8% n 135 · Phase 3 · secondary NCT01642004
  • 36.4% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 27.5% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 26.2% vs 29.7% n 187 · Phase 3 · secondary NCT02477826
  • 37.9% vs 29.7% n 177 · Phase 3 · secondary NCT02477826
  • 52.3% vs 29.7% n 377 · Phase 3 · secondary NCT02477826
  • 38.1% vs 29.7% n 126 · Phase 3 · secondary NCT02477826
  • 67.6% vs 64.5% n 287 · Phase 3 · secondary NCT04026412
  • 72.2% vs 64.5% n 320 · Phase 3 · secondary NCT04026412
  • 61.3% vs 57.9% n 287 · Phase 3 · secondary NCT04026412
  • 63.1% vs 57.9% n 320 · Phase 3 · secondary NCT04026412
  • 26.1% vs 33.5% n 211 · Phase 3 · secondary NCT02041533
  • 50.6% vs 43% wk 64 · n 158 · Phase 2 · primary NCT04623775
  • 14.5% 3 mg/kg · n 117 · Phase 2 · primary NCT01721759
  • 17.1% 480mg Q4W · n 129 · Phase 2 · secondary NCT03090737
  • 15.4% 3 mg/kg · n 117 · Phase 2 · secondary NCT01721759
  • 32.3% n 288 · Phase 2 · secondary NCT02659059
  • 47.2% n 36 · Phase 2 · secondary NCT02659059
Pembrolizumab
47.6% vs 18.9%+28.7 vs placebon 410NCT02578680
14 other results
  • 57.9% vs 38.4% n 278 · Phase 3 · secondary NCT02775435
  • 29% vs 27.1% n 245 · Phase 3 · secondary NCT03515837
  • 39.1% vs 32% wk 191 · n 299 · Phase 3 · secondary NCT02220894
  • 33.2% vs 28.9% wk 191 · n 413 · Phase 3 · secondary NCT02220894
  • 27.2% vs 26.5% wk 191 · n 637 · Phase 3 · secondary NCT02220894
  • 44.8% vs 27.8% n 154 · Phase 3 · secondary NCT02142738
  • 22.7% vs 14.3% n 185 · Phase 3 · secondary NCT03976375
  • 22.7% vs 12.5% n 185 · Phase 3 · secondary NCT03976375
  • 28.1% vs 7.1% n 114 · Phase 3 · secondary NCT02864394
  • 20.7% vs 5.7% n 213 · Phase 3 · secondary NCT02864394
  • 5.4% vs 11.1% n 37 · Phase 2 · primary NCT04165096
  • 71.4% n 112 · Phase 2 · primary NCT03631784
  • 75.5% n 102 · Phase 2 · primary NCT03631784
  • 22% vs 28% n 69 · Phase 2 · secondary NCT03971474

Duration of response, median

Nivolumab
11 vs 7+4 vs placebon 275NCT03117049
12 other results
Pembrolizumab
11.2 vs 7.8+3.4 vs placebon 195NCT02578680
8 other results
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety

Coverage. Nivolumab: 9 of 9 rows · Pembrolizumab: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricNivolumab
Rows use multiple source trials
Pembrolizumab
Rows use multiple source trials
Disease Control
responder rate · % of participants
87.3% (n=275) vs 89.8% (n=275) placeboa,b,c,d
NCT03117049 · Phase 3 · registry result, not featured evidence
75% (n=69) vs 73% (n=67) Standard of Care (Inv. Choice)a,b,c,d
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
Duration of Response
time to event · months
No placebo or comparator arm
35.45 months480mg Q4We,c,d
NCT03090737 · Phase 2 · registry result, not featured evidence
3 other source trials
16 months3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
12 months3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
NA months3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
12.5 monthsf,e,c,d
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
NA months
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
ORR
responder rate · % of participants
No placebo or comparator arm
17.1% (n=129)480mg Q4Wb,c,d
NCT03090737 · Phase 2 · registry result, not featured evidence
4 other source trials
32.3% (n=288)
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
47.2% (n=36)
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
14.5% (n=117)3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
15.4% (n=117)3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
71.4% (n=112)f,b,c,d
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
75.5% (n=102)
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
Overall Survival
time to event · months
No placebo or comparator arm
NA monthsf,g,b,d
NCT03158129 · Phase 2 · registry result, not featured evidence
show 3 more doses
NA months
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
20.7 monthsf,g,b,d
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
23 months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
PFS
time to event · months
No placebo or comparator arm
2 monthsf,g,e,d
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
2 months
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
7.1 monthsf,g,e,d
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
8.3 months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
Dropout rate
—480 mgh
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 43 more results
—3 mg/kg
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
1.7%Nivolumab
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—480 mg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—3 mg/kg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
3%Nivolumab
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
1.7%360 mg
NCT02998528 · Phase 3 · combination
0.9%3 mg/kg + 1 mg/kg
NCT02998528 · Phase 3 · combination
1.3%Part 1-Arm A: Nivolumab
NCT02477826 · Phase 3
1.3%Part 1-Arm B: Nivo + Ipi
NCT02477826 · Phase 3 · combination
1.1%Part 1-Arm D: Nivo + Ipi
NCT02477826 · Phase 3 · combination
2.8%Part 1-Arm G: Nivo + Chemo
NCT02477826 · Phase 3 · combination
0.5%Part 2 - Arm H: Nivolumab + Chemot
NCT02477826 · Phase 3 · combination
0%Part 3 -Arm J: Nivolumab + Ipilimu
NCT02477826 · Phase 3 · combination
66%
NCT03444766 · Phase 4 · registry result, not featured evidence
64.1%Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
56.9%Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
73.1%
NCT03117049 · Phase 3 · registry result, not featured evidence
0.3%
NCT02613507 · Phase 3 · registry result, not featured evidence
2.1%Arm A: Nivolumab Plus Platinum-dou
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
2.7%Arm B: Nivolumab Plus Ipilimumab
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
1.5%
NCT02041533 · Phase 3 · registry result, not featured evidence
1.1%480 mg every 4 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
1.6%240 mg every 2 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
—Cohort A: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Cohort B: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
n/a: no completion milestoneNivolumab Monotherapy (Not Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Nivolumab Monotherapy (Pre-Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
88.2%HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
90.6%Non-HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
2.5%Part 1: Treatment A
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
0%Part 2: Treatment C
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
8.7%Arm A - Nivolumab
NCT03158129 · Phase 2 · registry result, not featured evidence
23.8%Arm B - Nivolumab + Ipilimumab
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
0%Arm C - Nivolumab + Chemotherapy
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
9.1%Arm D - Nivolumab + Ipilimumab + C
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
—Pixatimod (PG545) + Nivolumab + Cy
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
0%Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
37.9%
NCT02350764 · Phase 2 · registry result, not featured evidence
—600 mg
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone480mg Q4W
NCT03090737 · Phase 2 · registry result, not featured evidence
87.2%Nivolumab+Ipilimumab
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
88.9%Nivolumab+Ipilimumab+Chemotherapy
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePembrolizumabi
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 48 more results
—Pembrolizumab First Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—Pembrolizumab Second Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
54%10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
58.8%2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
n/a: no completion milestonePembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
—Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
n/a: no completion milestone
NCT02775435 · Phase 3 · combination
n/a: no completion milestone
NCT02220894 · Phase 3
n/a: no completion milestone
NCT02504372 · Phase 3
89.3%200 mg IV Q3W
NCT03715205 · Phase 4 · registry result, not featured evidence
—Pembrolizumab (First Course) + Ola
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (First Course) + Pem
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (Second Course) + Ol
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (Second Course) + Pe
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Olaparib (Maintena
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Pemetrexed (Mainte
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
33%Pembrolizumab + Pemetrexed + Plati
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
0%Arm 1 Stereotactic Body Radiation
NCT03867175 · Phase 3 · registry result, not featured evidence · combination
0%Arm 2 Pembrolizumab Only
NCT03867175 · Phase 3 · registry result, not featured evidence
—Pembrolizumab + Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestonePembrolizumab+Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT03875092 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT03950674 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT02864394 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT03850444 · Phase 3 · registry result, not featured evidence
2.5%
NCT03634241 · Phase 2 · registry result, not featured evidence
90.5%Arm B (SCCHN)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
60%Arm C (mUBC)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone800 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone200 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestonePembrolizumab + Lenvatinib
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestonePembrolizumab + Quavonlimab
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT04165096 · Phase 2 · registry result, not featured evidence · combination
0%Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
50%Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
80.7%1st Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
89.2%2nd Line HNSCC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
94.4%2nd Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02955758 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePembrolizumab + cCRT + Paclitaxel
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestonePembrolizumab + cCRT + Pemetrexed
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
3.2%
NCT02733159 · Phase 2 · registry result, not featured evidence
87.7%
NCT03004183 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
86.4%
NCT03087760 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—480 mgh
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 43 more results
—3 mg/kg
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
0.3%Nivolumab
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—480 mg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—3 mg/kg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
0.7%Nivolumab
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
0.6%360 mg
NCT02998528 · Phase 3 · combination
0%3 mg/kg + 1 mg/kg
NCT02998528 · Phase 3 · combination
0.3%Part 1-Arm A: Nivolumab
NCT02477826 · Phase 3
0%Part 1-Arm B: Nivo + Ipi
NCT02477826 · Phase 3 · combination
0.5%Part 1-Arm D: Nivo + Ipi
NCT02477826 · Phase 3 · combination
0%Part 1-Arm G: Nivo + Chemo
NCT02477826 · Phase 3 · combination
0.3%Part 2 - Arm H: Nivolumab + Chemot
NCT02477826 · Phase 3 · combination
0%Part 3 -Arm J: Nivolumab + Ipilimu
NCT02477826 · Phase 3 · combination
6%
NCT03444766 · Phase 4 · registry result, not featured evidence
—Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
—Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
—
NCT03117049 · Phase 3 · registry result, not featured evidence
—
NCT02613507 · Phase 3 · registry result, not featured evidence
0.7%Arm A: Nivolumab Plus Platinum-dou
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
0%Arm B: Nivolumab Plus Ipilimumab
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
—
NCT02041533 · Phase 3 · registry result, not featured evidence
—480 mg every 4 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
—240 mg every 2 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
—Cohort A: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Cohort B: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
3.8%Nivolumab Monotherapy (Not Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Nivolumab Monotherapy (Pre-Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
11.8%HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
5%Non-HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
—Part 1: Treatment A
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
—Part 2: Treatment C
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
0%Arm A - Nivolumab
NCT03158129 · Phase 2 · registry result, not featured evidence
4.8%Arm B - Nivolumab + Ipilimumab
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
0%Arm C - Nivolumab + Chemotherapy
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
0%Arm D - Nivolumab + Ipilimumab + C
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
—Pixatimod (PG545) + Nivolumab + Cy
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
—Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
13.8%
NCT02350764 · Phase 2 · registry result, not featured evidence
—600 mg
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
5.4%480mg Q4W
NCT03090737 · Phase 2 · registry result, not featured evidence
11.1%Nivolumab+Ipilimumab
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
11.1%Nivolumab+Ipilimumab+Chemotherapy
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
9.4%3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
8.4%Pembrolizumabi
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 48 more results
—Pembrolizumab First Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—Pembrolizumab Second Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
4.9%10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
6.7%2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
—Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
11.5%
NCT02775435 · Phase 3 · combination
19.9%
NCT02220894 · Phase 3
—
NCT02504372 · Phase 3
—200 mg IV Q3W
NCT03715205 · Phase 4 · registry result, not featured evidence
—Pembrolizumab (First Course) + Ola
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (First Course) + Pem
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (Second Course) + Ol
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (Second Course) + Pe
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Olaparib (Maintena
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Pemetrexed (Mainte
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Pemetrexed + Plati
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Arm 1 Stereotactic Body Radiation
NCT03867175 · Phase 3 · registry result, not featured evidence · combination
—Arm 2 Pembrolizumab Only
NCT03867175 · Phase 3 · registry result, not featured evidence
—Pembrolizumab + Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab+Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
—
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
3.1%
NCT03875092 · Phase 3 · registry result, not featured evidence · combination
—
NCT03950674 · Phase 3 · registry result, not featured evidence · combination
—
NCT02864394 · Phase 3 · registry result, not featured evidence
12.5%
NCT03850444 · Phase 3 · registry result, not featured evidence
—
NCT03634241 · Phase 2 · registry result, not featured evidence
—Arm B (SCCHN)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
—Arm C (mUBC)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
—800 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
—200 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
—Pembrolizumab + Lenvatinib
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
—Pembrolizumab + Quavonlimab
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
—
NCT04165096 · Phase 2 · registry result, not featured evidence · combination
—Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
—Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
—1st Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
—2nd Line HNSCC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
—2nd Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
—
NCT02955758 · Phase 2 · registry result, not featured evidence
—Pembrolizumab + cCRT + Paclitaxel
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
—Pembrolizumab + cCRT + Pemetrexed
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
1.6%
NCT02733159 · Phase 2 · registry result, not featured evidence
12.3%
NCT03004183 · Phase 2 · registry result, not featured evidence
11.6%
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
—
NCT03087760 · Phase 2 · registry result, not featured evidence
Serious AEs
33.3%480 mgh
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 43 more results
59.9%3 mg/kg
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—Nivolumab
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
16.7%480 mg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
64.9%3 mg/kg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—Nivolumab
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
30.1%360 mg
NCT02998528 · Phase 3 · combination
27%3 mg/kg + 1 mg/kg
NCT02998528 · Phase 3 · combination
61.1%Part 1-Arm A: Nivolumab
NCT02477826 · Phase 3
70.3%Part 1-Arm B: Nivo + Ipi
NCT02477826 · Phase 3 · combination
69.2%Part 1-Arm D: Nivo + Ipi
NCT02477826 · Phase 3 · combination
65.1%Part 1-Arm G: Nivo + Chemo
NCT02477826 · Phase 3 · combination
64%Part 2 - Arm H: Nivolumab + Chemot
NCT02477826 · Phase 3 · combination
61.9%Part 3 -Arm J: Nivolumab + Ipilimu
NCT02477826 · Phase 3 · combination
30%
NCT03444766 · Phase 4 · registry result, not featured evidence
63.8%Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
56.9%Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
56.4%
NCT03117049 · Phase 3 · registry result, not featured evidence
54.3%
NCT02613507 · Phase 3 · registry result, not featured evidence
54.6%Arm A: Nivolumab Plus Platinum-dou
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
64.8%Arm B: Nivolumab Plus Ipilimumab
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
73%
NCT02041533 · Phase 3 · registry result, not featured evidence
34.8%480 mg every 4 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
39.4%240 mg every 2 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
44.9%Cohort A: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
41.6%Cohort B: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Nivolumab Monotherapy (Not Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
60.9%Nivolumab Monotherapy (Pre-Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
70.6%HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
41%Non-HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
59.7%Part 1: Treatment A
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
65.2%Part 2: Treatment C
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
17.4%Arm A - Nivolumab
NCT03158129 · Phase 2 · registry result, not featured evidence
14.3%Arm B - Nivolumab + Ipilimumab
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
31.8%Arm C - Nivolumab + Chemotherapy
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
13.6%Arm D - Nivolumab + Ipilimumab + C
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
37.5%Pixatimod (PG545) + Nivolumab + Cy
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
20%Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
75.9%
NCT02350764 · Phase 2 · registry result, not featured evidence
100%600 mg
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
43.4%480mg Q4W
NCT03090737 · Phase 2 · registry result, not featured evidence
59.4%Nivolumab+Ipilimumab
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
72.2%Nivolumab+Ipilimumab+Chemotherapy
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
75.2%3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
—Pembrolizumabi
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 48 more results
51.3%Pembrolizumab First Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
16.7%Pembrolizumab Second Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
38.8%10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
36.6%2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
57.5%Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
22.2%Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
46%
NCT02775435 · Phase 3 · combination
41%
NCT02220894 · Phase 3
24.5%
NCT02504372 · Phase 3
20.7%200 mg IV Q3W
NCT03715205 · Phase 4 · registry result, not featured evidence
35%Pembrolizumab (First Course) + Ola
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
37.7%Pembrolizumab (First Course) + Pem
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
0%Pembrolizumab (Second Course) + Ol
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
7.7%Pembrolizumab (Second Course) + Pe
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Olaparib (Maintena
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Pemetrexed (Mainte
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
23.4%Pembrolizumab + Pemetrexed + Plati
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
50%Arm 1 Stereotactic Body Radiation
NCT03867175 · Phase 3 · registry result, not featured evidence · combination
100%Arm 2 Pembrolizumab Only
NCT03867175 · Phase 3 · registry result, not featured evidence
54.7%Pembrolizumab + Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab+Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
35.1%
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
53.8%
NCT03875092 · Phase 3 · registry result, not featured evidence · combination
36%
NCT03950674 · Phase 3 · registry result, not featured evidence · combination
36.2%
NCT02864394 · Phase 3 · registry result, not featured evidence
32.8%
NCT03850444 · Phase 3 · registry result, not featured evidence
7.5%
NCT03634241 · Phase 2 · registry result, not featured evidence
9.5%Arm B (SCCHN)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
20%Arm C (mUBC)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
60.8%800 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
46.7%200 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
52.5%Pembrolizumab + Lenvatinib
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
47.6%Pembrolizumab + Quavonlimab
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
37.8%
NCT04165096 · Phase 2 · registry result, not featured evidence · combination
10.8%Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
20%Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
47.4%1st Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
54.1%2nd Line HNSCC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
25%2nd Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
36%
NCT02955758 · Phase 2 · registry result, not featured evidence
58.9%Pembrolizumab + cCRT + Paclitaxel
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
45.1%Pembrolizumab + cCRT + Pemetrexed
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
85%
NCT02733159 · Phase 2 · registry result, not featured evidence
51.8%
NCT03004183 · Phase 2 · registry result, not featured evidence
40.6%
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
45.5%
NCT03087760 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
480 mgh
cough 33.3%
arthralgia 20%
rash 20%
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 40 more results
3 mg/kg
fatigue 33.4%
decreased appetite 31.7%
cough 28.9%
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
480 mg
nausea 33.3%
vomiting 33.3%
abdominal pain 16.7%
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
3 mg/kg
dyspnoea 35.9%
cough 34.4%
fatigue 32.1%
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
360 mg
nausea 41.5%
constipation 35.8%
anaemia 35.2%
NCT02998528 · Phase 3 · combination
3 mg/kg + 1 mg/kg
constipation 21.6%
fatigue 21.6%
nausea 21.6%
NCT02998528 · Phase 3 · combination
decreased appetite 24.8%
dyspnoea 23.8%
diarrhoea 22.5%
NCT02477826 · Phase 3
decreased appetite 33.2%
fatigue 27.4%
diarrhoea 26.1%
NCT02477826 · Phase 3 · combination
decreased appetite 33%
dyspnoea 25.4%
diarrhoea 23.8%
NCT02477826 · Phase 3 · combination
anaemia 46.5%
nausea 45.9%
constipation 36.6%
NCT02477826 · Phase 3 · combination
anaemia 46.4%
nausea 33.6%
decreased appetite 28%
NCT02477826 · Phase 3 · combination
anaemia 50%
hyponatraemia 37.3%
aspartate aminotransferase increased 36.5%
NCT02477826 · Phase 3 · combination
cough 24%
pyrexia 21%
vomiting 17%
NCT03444766 · Phase 4 · registry result, not featured evidence
anaemia 44%
nausea 34.8%
constipation 29.1%
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
anaemia 41.5%
nausea 32.7%
cough 26.1%
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
constipation 54.9% (placebo 48.7%)
alopecia 52.4% (placebo 54.5%)
peripheral sensory neuropathy 44.3% (placebo 42.2%)
NCT03117049 · Phase 3 · registry result, not featured evidence
anaemia 34.7%
decreased appetite 31.5%
fatigue 31.2%
NCT02613507 · Phase 3 · registry result, not featured evidence
anaemia 46.8%
nausea 44.7%
constipation 36.9%
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
constipation 29.6%
pruritus 25.4%
diarrhoea 23.9%
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
fatigue 40.4%
decreased appetite 34.1%
nausea 32.2%
NCT02041533 · Phase 3 · registry result, not featured evidence
480 mg every 4 weeks
diarrhoea 16.9%
pruritus 16.9%
fatigue 15.7%
NCT02713867 · Phase 3 · registry result, not featured evidence
240 mg every 2 weeks
pruritus 23.3%
diarrhoea 22.8%
fatigue 22.2%
NCT02713867 · Phase 3 · registry result, not featured evidence
diarrhoea 28.3%
arthralgia 23.6%
upper respiratory tract infection 22%
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
cough 17.6%
weight decreased 16%
arthralgia 14.4%
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
fatigue 36.1%
dyspnoea 23.7%
nausea 23.2%
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
anaemia 41.2%
cough 41.2%
hyponatraemia 35.3%
NCT03195491 · Phase 3 · registry result, not featured evidence
anaemia 40.5%
decreased appetite 24.5%
cough 22.2%
NCT03195491 · Phase 3 · registry result, not featured evidence
anaemia 66.2%
fatigue 42.9%
nausea 42.9%
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
anaemia 69%
nausea 34.8%
thrombocytopenia 29.7%
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
fatigue 34.8%
anemia 30.4%
rash acneiform 26.1%
NCT03158129 · Phase 2 · registry result, not featured evidence
rash acneiform 61.9%
cough 38.1%
fatigue 38.1%
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
nausea 81.8%
fatigue 72.7%
anemia 54.5%
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
anemia 50%
diarrhea 40.9%
nausea 40.9%
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
anemia 62.5%
fatigue 50%
hyponatremia 50%
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
activated partial thromboplastin time prolonged 80%
hypertriglyceridemia 60%
hyponatremia 60%
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
hyperglycemia 100%
hypoalbuminemia 93.1%
anemia 75.9%
NCT02350764 · Phase 2 · registry result, not featured evidence
600 mg
blood alkaline phosphatase increased 100%
blood lactate dehydrogenase increased 100%
bronchitis 100%
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
480mg Q4W
anaemia 28.7%
blood alkaline phosphatase increased 24.8%
rash 20.2%
NCT03090737 · Phase 2 · registry result, not featured evidence
fatigue 55.2%
diarrhoea 38.5%
nausea 38.2%
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
fatigue 55.6%
pruritus 47.2%
nausea 44.4%
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
3 mg/kg
fatigue 53%
decreased appetite 39.3%
dyspnoea 38.5%
NCT01721759 · Phase 2 · registry result, not featured evidence
i
diarrhoea 26.6%
dyspnoea 26.6%
fatigue 24%
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 42 more results
upper respiratory tract infection 33.3%
constipation 16.7%
decreased appetite 16.7%
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
10 mg/kg
fatigue 25.7%
decreased appetite 23.3%
dyspnoea 23%
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
2 mg/kg
decreased appetite 30.7%
fatigue 30.1%
nausea 25.7%
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
nausea 57.3% (placebo 51%)
anaemia 45.9% (placebo 45%)
fatigue 42.7% (placebo 39.6%)
NCT02578680 · Phase 3 · combination
abdominal pain 22.2% (placebo 6.4%)
cough 22.2% (placebo 30.7%)
diarrhoea 22.2% (placebo 20.3%)
NCT02578680 · Phase 3 · combination
anaemia 53.2% (placebo 49.6%)
alopecia 46% (placebo 37.5%)
nausea 36.3% (placebo 32.1%)
NCT02775435 · Phase 3 · combination
decreased appetite 17%
cough 16.8%
dyspnoea 16.5%
NCT02220894 · Phase 3
weight increased 22.8% (placebo 28.9%)
pruritus 21.6% (placebo 12.7%)
hypothyroidism 20.7% (placebo 4.6%)
NCT02504372 · Phase 3
200 mg IV Q3W
hypothyroidism 17.3%
anaemia 12.7%
constipation 11.3%
NCT03715205 · Phase 4 · registry result, not featured evidence
anaemia 36.2%
nausea 24%
fatigue 17.2%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anaemia 37.7%
nausea 19%
aspartate aminotransferase increased 16.6%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anaemia 14.3%
covid-19 14.3%
headache 14.3%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anaemia 15.4%
cough 15.4%
productive cough 15.4%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anaemia 38.4%
nausea 30.9%
neutropenia 23.4%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anemia 75%
cough 75%
abdominal pain 50%
NCT03867175 · Phase 3 · registry result, not featured evidence · combination
alanine aminotransferase increased 100%
alkaline phosphatase increased 100%
aspartate aminotransferase increased 100%
NCT03867175 · Phase 3 · registry result, not featured evidence
hypertension 41.4%
diarrhoea 40.9%
hypothyroidism 35.4%
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
anaemia 40.4% (placebo 44.7%)
nausea 39.2% (placebo 43.5%)
neutrophil count decreased 36.7% (placebo 45.9%)
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
alopecia 78.5%
white blood cell count decreased 78.5%
neutrophil count decreased 76.9%
NCT03875092 · Phase 3 · registry result, not featured evidence · combination
nausea 72% (placebo 53.3%)
constipation 64% (placebo 73.3%)
decreased appetite 56% (placebo 60%)
NCT03950674 · Phase 3 · registry result, not featured evidence · combination
anaemia 33.3%
aspartate aminotransferase increased 21.6%
cough 21.6%
NCT02864394 · Phase 3 · registry result, not featured evidence
anaemia 30.5%
cough 23.4%
pyrexia 22.7%
NCT03850444 · Phase 3 · registry result, not featured evidence
fatigue 45%
investigations 25%
alanine aminotransferase increased 20%
NCT03634241 · Phase 2 · registry result, not featured evidence
anaemia 42.9%
diarrhoea 33.3%
fatigue 28.6%
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
asthenia 40%
blood creatinine increased 40%
blood urea increased 40%
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
800 mg
diarrhoea 29.4%
fatigue 21.6%
alanine aminotransferase increased 19.6%
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
200 mg
pyrexia 23.3%
constipation 20%
decreased appetite 20%
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
hypertension 52.5%
diarrhoea 45%
hypothyroidism 36.3%
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
pruritus 29.3%
cough 22%
fatigue 20.7%
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
fatigue 29.7%
pruritus 29.7%
nausea 24.3%
NCT04165096 · Phase 2 · registry result, not featured evidence · combination
headache 40.5%
fatigue 24.3%
rash 21.6%
NCT02681549 · Phase 2 · registry result, not featured evidence
anorexia 40%
gastrointestinal disorders - other, specify 40%
hypertension 40%
NCT02681549 · Phase 2 · registry result, not featured evidence
asthenia 34.2%
dyspnoea 34.2%
cough 29.8%
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
asthenia 21.6%
anaemia 18.9%
cough 18.9%
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
decreased appetite 36.1%
dyspnoea 36.1%
cough 30.6%
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
nausea 24%
decreased appetite 20%
worsening abdominal pain 20%
NCT02955758 · Phase 2 · registry result, not featured evidence
anaemia 39.3%
fatigue 34.8%
alopecia 31.3%
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
nausea 52%
asthenia 40.2%
anaemia 32.4%
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
fatigue 60%
dyspnea 48.3%
cough 35%
NCT02733159 · Phase 2 · registry result, not featured evidence
fatigue 21.4%
nausea 12.5%
back pain 10.7%
NCT03004183 · Phase 2 · registry result, not featured evidence
fatigue 56.5%
hypoalbuminemia 44.9%
hyponatremia 39.1%
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
esophagitis 36.4%
fatigue 36.4%
hypothyroidism 22.7%
NCT03087760 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 2 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.
  5. ePopulation context differs: registered conditions differ.
  6. fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  7. gTrial phases differ: Phase 3 versus Phase 2.
  8. hPopulation comparability has not been reviewed for 38 of these studies.
  9. iPopulation comparability has not been reviewed for 42 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Nivolumab

Time to Response 2.1 vs 2.73 Docetaxel months
time to event · months
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 5 more results
2.23 vs 2.09 Docetaxel months
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
2.92 vs 2.92 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
2.96 vs 2.92 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
2.96 vs 2.89 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
2.92 vs 2.89 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
Disease-related Symptom Improvement 17.8% (n=292) vs 19.7% (n=290) Docetaxel @ 12wk
responder rate · % of participants
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 2 more results
18.5% (n=135) vs 21.2% (n=137) Docetaxel @ 12wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
35.4% (n=271) vs 33.7% (n=270) Investigator Choice of Chemotherapy @ 12wk
NCT02041533 · Phase 3 · registry result, not featured evidence
Overall Survival 63.7% (n=135) vs 50.7% (n=137) Docetaxel @ 26wk
absolute value · percentage points
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 11 more results
42.2% (n=135) vs 24.3% (n=137) Docetaxel @ 52wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
28.1% (n=135) vs 12.5% (n=137) Docetaxel @ 78wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
63.7% (n=135) vs 50.4% (n=137) Docetaxel @ 26wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
42.2% (n=135) vs 24.1% (n=137) Docetaxel @ 52wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
28.1% (n=135) vs 12.4% (n=137) Docetaxel @ 78wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
23% (n=135) vs 8% (n=137) Docetaxel @ 104wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
15.6% (n=135) vs 5.8% (n=137) Docetaxel @ 156wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
13.1% (n=135) vs 4.4% (n=137) Docetaxel @ 208wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
12.3% (n=135) vs 3.6% (n=137) Docetaxel @ 260wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
11.4% (n=135) vs 2.7% (n=137) Docetaxel @ 312wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
9.6% (n=135) vs 0% (n=137) Docetaxel @ 364wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
PFS 38.4% (n=135) vs 22.6% (n=137) Docetaxel @ 26wk
responder rate · % of participants
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 8 more results
21% (n=135) vs 7.2% (n=137) Docetaxel @ 52wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
15.87% (n=135) vs 1.8% (n=137) Docetaxel @ 78wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
14.8% (n=135) vs NA Docetaxel @ 104wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
11% (n=135) vs NA Docetaxel @ 156wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
8.9% (n=135) vs NA Docetaxel @ 208wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
8.9% (n=135) vs NA Docetaxel @ 260wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
7.6% (n=135) vs NA Docetaxel @ 312wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
6.1% (n=135) vs NA Docetaxel @ 364wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Event-Free Survival 31.57 vs 20.8 Platinum Doublet Chemo months360 mg
time to event · months
NCT02998528 · Phase 3 · combination
show 1 more result
59.6 vs 21.06 Platinum Doublet Chemo months360 mg
NCT02998528 · Phase 3 · combination
Pathologic Complete 24% (n=179) vs 2.2% (n=179) Platinum Doublet Chemo360 mg
responder rate · % of participants
NCT02998528 · Phase 3 · combination · converted to % from 43 Participants as posted
Major Pathologic 36.9% (n=179) vs 8.9% (n=179) Platinum Doublet Chemo360 mg
responder rate · % of participants
NCT02998528 · Phase 3 · combination · converted to % from 66 Participants as posted
Time to Death or Distant Metastasis 64.66 vs 36.76 Platinum Doublet Chemo months360 mg
time to event · months
NCT02998528 · Phase 3 · combination
show 2 more results
30.65 vs 30.36 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
36.14 vs 30.36 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
LCSS Symptom Deterioration 31.3% (n=396) vs 25.7% (n=397) Chemotherapy @ 12wk
ratio to baseline · % of baseline
NCT02477826 · Phase 3 · combination
show 5 more results
35.4% (n=396) vs 25.7% (n=397) Chemotherapy @ 12wk
NCT02477826 · Phase 3
33.2% (n=187) vs 25.7% (n=397) Chemotherapy @ 12wk
NCT02477826 · Phase 3 · combination
28.8% (n=177) vs 25.7% (n=397) Chemotherapy @ 12wk
NCT02477826 · Phase 3 · combination
30% (n=377) vs 25.7% (n=397) Chemotherapy @ 12wk
NCT02477826 · Phase 3 · combination
23% (n=126) vs 25.7% (n=397) Chemotherapy @ 12wk
NCT02477826 · Phase 3 · combination
NSCLC-SAQ Total -0.6 vs -0.89 Durva score @ 48wk
absolute change · score
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
-0.91 vs -0.89 Durva score @ 48wk
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
Complete 5.1% (n=275) vs 2.9% (n=275) placebo
responder rate · % of participants
Complete response
NCT03117049 · Phase 3 · registry result, not featured evidence · converted to % from 14 Participants as posted
Partial 56.4% (n=275) vs 47.6% (n=275) placebo
responder rate · % of participants
Partial response
NCT03117049 · Phase 3 · registry result, not featured evidence · converted to % from 155 Participants as posted

+ 32 further endpoints in the CSV export.

Pembrolizumab

PFS Rate at 6 62.1% (n=154) vs 50.3% (n=151) SOC Chemotherapy @ 24wk
responder rate · % of participants
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
OS Rate at 12 70.3% (n=154) vs 54.8% (n=151) SOC Chemotherapy @ 48wk
responder rate · % of participants
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Overall Survival 12.7 vs 8.5 Docetaxel months10 mg/kg
time to event · months
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
10.4 vs 8.5 Docetaxel months2 mg/kg
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
PFS 4 vs 4 Docetaxel months10 mg/kg
time to event · months
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
3.9 vs 4 Docetaxel months2 mg/kg
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
ORR 18.5% (n=346) vs 9.3% (n=343) Docetaxel10 mg/kg
responder rate · % of participants
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
18% (n=344) vs 9.3% (n=343) Docetaxel2 mg/kg
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
Duration of Response NA vs 6.23 Docetaxel months10 mg/kg
time to event · months
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
NA vs 6.23 Docetaxel months2 mg/kg
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
Disease-free Survival 53.8 vs 43 placebo months
time to event · months
NCT02504372 · Phase 3
show 3 more results
67 vs 47.6 placebo months
NCT02504372 · Phase 3
58.7 vs 42.8 placebo months
NCT02504372 · Phase 3
53.6 vs 42 placebo months @ 295wk
NCT02504372 · Phase 3
EORTC QLQ-C30 GHS -5.34 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
-3.44 score @ 24wk
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
Time to Deterioration Global Health Status 19.81 months
time to event · months
No placebo or comparator arm
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
17.28 months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-LC13 -1.98 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
-1.82 score @ 24wk
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
-0.82 score @ 24wk
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
-0.47 score @ 24wk
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
Time to Deterioration QLQ-LC13 NA months
time to event · months
No placebo or comparator arm
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
NA months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
NA months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
NA months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Dyspnoea -0.16 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
1.35 score @ 24wk
NCT03976323 · Phase 3 · registry result, not featured evidence · combination

+ 39 further endpoints in the CSV export.

Urothelial Carcinoma

Shared mechanism: PD-1 · full Urothelial Carcinoma pipeline

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Urothelial Carcinomamonoclonal antibody
Partial signal

NCT03036098 · Phase 3 · completed

This was a large randomized trial against standard chemotherapy, but it was open-label. Three of the four primary comparisons were statistically significant, while overall survival in PD-L1 positive patients given nivolumab plus ipilimumab has no posted significance test, so the overall result is mixed.

Next expected readout: December 2026 · NCT06682728 (registry estimate)

Reported efficacy

Overall Survival (OS) in Cisplatin-ineligible Randomized Participants for Primary Study (From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)); Overall Survival (OS) in Programmed Death-Ligand 1 (PD-L1) Positive (≥ 1%) Randomized Participants by Immunohistochemistry (IHC) for Primary Study (From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)); Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] in Cisplatin-eligible Participants for Sub-study (From the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurs first (up to approximately 89 months)); Overall Survival (OS) in Cisplatin-eligible Participants for Sub-study (From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)): Sub-study (cisplatin-eligible), nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin: PFS HR 0.72 (95% CI 0.59 to 0.88), p=0.0018; OS median 21.7 vs 18.9 months, HR 0.78 (95% CI 0.63 to 0.96), p=0.0171. Primary study, nivolumab + ipilimumab vs chemotherapy: OS in PD-L1 >=1% 16.3 vs 14.4 months, primary not met per BMS; OS in cisplatin-ineligible 19.1 vs 13.2 months, HR 0.79 (95% CI 0.64 to 0.97), posted p=0.0032 (CT.gov posted results). (mixed)

Result source: NCT03036098

Pembrolizumab

Marketed by Merck & Co.

Approved in Urothelial Carcinomamonoclonal antibody
Partial signal

NCT04223856 · Phase 3 · active, not recruiting

The trial was randomized and actively controlled, with 442 participants assigned to enfortumab vedotin plus pembrolizumab and 444 to chemotherapy, but treatment assignment was not blinded. Both primary endpoints were met in favor of the combination: independently reviewed progression-free survival and overall survival were significantly improved, but the open-label design and lack of a reported power calculation in the provided record support a moderate grade rather than a strong one.

Next expected readout: December 2026 · NCT04164082 (registry estimate)

Reported efficacy

Pembro Combo vs Chemo: Progression-free Survival (PFS) Using Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) (Up to approximately 42 months); Pembro Combo vs Chemo: Overall Survival (OS) (Up to approximately 42 months); Pembro vs Chemo: OS in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10% (Up to approximately 42 months); Pembro vs Chemo: OS (Up to approximately 42 months): Pembrolizumab plus chemotherapy vs chemotherapy: PFS median 8.3 vs 7.1 months (HR 0.78, 95% CI 0.65 to 0.93; p=0.0033 against a boundary of 0.0019); OS median 17.0 vs 14.3 months (HR 0.86, 95% CI 0.72 to 1.02; p=0.0407 against a boundary of 0.0142). Pembrolizumab monotherapy OS comparisons were exploratory after the hierarchy stopped (KEYNOTE-361, Lancet Oncol 2021). (missed)

Result source: NCT02853305

Results for Urothelial Carcinoma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

Coverage. Nivolumab: 3 of 4 rows · Pembrolizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricNivolumabPembrolizumab
Dropout rate
0%0.009 mg/kg q3w + 360 mg q3wa
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
show 9 more results
0%0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
20%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
17.2%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
10.5%Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
25%Experimental: Expansion 1a
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
show 15 more results
0%Experimental: Expansion 2
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
4.8%Experimental: Expansion 3
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
0%Experimental: Safety Lead In
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
57.1%20 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
—12.5 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—0.009 mg/kg q3w + 360 mg q3wa
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
show 9 more results
—0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Experimental: Expansion 1a
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
show 15 more results
—Experimental: Expansion 2
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
—Experimental: Expansion 3
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
—Experimental: Safety Lead In
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
1.6%100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—20 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
—12.5 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
Serious AEs
66.7%0.009 mg/kg q3w + 360 mg q3wa
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
show 9 more results
50%0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
36%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
44.7%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
60%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
62.5%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
42.1%Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
66.7%Experimental: Expansion 1a
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
show 15 more results
60%Experimental: Expansion 2
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
35%Experimental: Expansion 3
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
16.7%Experimental: Safety Lead In
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
45%300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
51%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
40%50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
0%25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
38.2%100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
35.7%75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
37.5%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
14.3%20 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
—12.5 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
0.009 mg/kg q3w + 360 mg q3wa
pyrexia 100%
rash 100%
chills 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
show 9 more results
0.006 mg/kg q3w + 240 mg q2w
arthralgia 100%
fatigue 100%
headache 100%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q2w + 240 mg q2w
chills 100%
pyrexia 100%
back pain 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 360 mg q3w
fatigue 76%
chills 64%
cough 60%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 360 mg q3w
fatigue 50.6%
pyrexia 47.9%
nausea 40.1%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.003 mg/kg q2w + 240 mg q2w
chills 100%
nasal congestion 100%
arthralgia 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 90%
diarrhoea 80%
nausea 80%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
diarrhoea 75%
influenza like illness 75%
pruritus 75%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
decreased appetite 100%
fatigue 100%
influenza like illness 100%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 78.9%
influenza like illness 68.4%
nausea 57.9%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
a
decreased appetite 50%
alanine aminotransferase increased 33.3%
diarrhea 33.3%
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
show 12 more results
anaemia 80%
dizziness 80%
fatigue 80%
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
dizziness 45%
decreased appetite 30%
dyspnea 30%
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
abdominal pain 66.7%
blood alkaline phosphatase increased 66.7%
fatigue 66.7%
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
300 mg BID + 200 mg Q3W
fatigue 65%
nausea 55%
vomiting 50%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 50%
back pain 38.9%
diarrhoea 38.9%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 48.4%
nausea 30.1%
cough 26.2%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50 mg BID + 200 mg Q3W
fatigue 65%
arthralgia 45%
nausea 45%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
25 mg BID + 200 mg Q3W
arthralgia 100%
constipation 75%
cough 75%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg
diarrhoea 25.2%
constipation 23.6%
fatigue 23.6%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
75 mg
aspartate aminotransferase increased 21.4%
back pain 21.4%
fatigue 21.4%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
50 mg
fatigue 37.5%
diarrhoea 25%
decreased appetite 18.8%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
20 mg/kg
hypertension 28.6%
anemia 14.3%
arthralgia 14.3%
NCT03236935 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Nivolumab

ORR 14.9% (n=429)0.006 mg/kg q3w + 360 mg q3w
event count · % of participants
No placebo or comparator arm
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 64 Participants as posted
show 1 more result
17.6% (n=17)*
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted

Pembrolizumab

ORR 0% (n=10)100 mg
responder rate · % of participants
No placebo or comparator arm
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 3 more results
11% (n=118)100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
7.7% (n=13)75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
10% (n=10)50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Complete 0% (n=10)100 mg
responder rate · % of participants
No placebo or comparator arm
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 3 more results
1.7% (n=118)100 mg
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0% (n=13)75 mg
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0% (n=10)50 mg
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Partial 0% (n=10)100 mg
responder rate · % of participants
No placebo or comparator arm
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 3 more results
9.3% (n=118)100 mg
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
7.7% (n=13)75 mg
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
10% (n=10)50 mg
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Duration of Response 12.4 months100 mg
time to event · months
No placebo or comparator arm
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 2 more results
NA months75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
NA months50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
PFS 2.1 months100 mg
time to event · months
No placebo or comparator arm
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 3 more results
3 months100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
2.6 months75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
2.1 months50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination

Hepatocellular Carcinoma

Shared mechanism: PD-1 · full Hepatocellular Carcinoma pipeline

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Hepatocellular Carcinomamonoclonal antibody
Partial signal

NCT04039607 · Phase 3 · completed

This was a large randomized phase 3 trial against an active comparator, and its primary endpoint, overall survival, was met with statistical significance. Patients and doctors knew which treatment was given, but survival is an objective outcome that this knowledge cannot change; an open-label design still keeps the evidence below the top level.

Next expected readout: December 2026 · NCT07176650 (registry estimate)

No aligned efficacy figure on record for this race.

Pembrolizumab

Marketed by Merck & Co.

Approved in Hepatocellular Carcinomamonoclonal antibody
Reliable signal

NCT03062358 · Phase 3 · completed

Patients were randomly assigned 2:1 to pembrolizumab or placebo, with patients and investigators blinded. Overall survival, the primary endpoint, was significantly longer with pembrolizumab (hazard ratio 0.79, 95% CI 0.63 to 0.99, one-sided p=0.0180). The protocol reports a power calculation for overall survival and 453 patients were enrolled against a planned 450.

Next expected readout: December 2026 · NCT03419481 (registry estimate)

Reported efficacy

Overall Survival (OS) (Up to approximately 4 years): Overall Survival (OS) (Up to approximately 4 years): Pembrolizumab + BSC 14.6 Months (95% CI 12.6 to 18) | Placebo + BSC 13 Months (95% CI 10.5 to 15.1) (met)

Result source: NCT03062358

Results for Hepatocellular Carcinoma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Pembrolizumab
Overall Survival (OS) (Up to approximately 4 years): Pembrolizumab + BSC 14.6 Months (95% CI 12.6 to 18) | Placebo + BSC 13 Months (95% CI 10.5 to 15.1) NCT03062358 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

Coverage. Nivolumab: 4 of 4 rows · Pembrolizumab: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricNivolumabPembrolizumab
Dropout rate
0%Galunisertib + Nivolumab (Cohort 1a
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
show 5 more results
20%Galunisertib + Nivolumab (Cohort 2
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
0%Galunisertib + Nivolumab (Cohort 3
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
0%Galunisertib + Nivolumab (Cohort 4
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
—Galunisertib + Nivolumab (HCC) Pha
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
—Galunisertib + Nivolumab (NSCLC) P
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone300 mg BID + 200 mg Q3Wa
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
show 4 more results
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
0%Galunisertib + Nivolumab (Cohort 1a
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
show 5 more results
0%Galunisertib + Nivolumab (Cohort 2
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
0%Galunisertib + Nivolumab (Cohort 3
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
0%Galunisertib + Nivolumab (Cohort 4
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
—Galunisertib + Nivolumab (HCC) Pha
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
—Galunisertib + Nivolumab (NSCLC) P
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg BID + 200 mg Q3Wa
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
show 4 more results
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
33.3%Galunisertib + Nivolumab (Cohort 1a
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
show 5 more results
40%Galunisertib + Nivolumab (Cohort 2
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Galunisertib + Nivolumab (Cohort 3
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
50%Galunisertib + Nivolumab (Cohort 4
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
0%Galunisertib + Nivolumab (HCC) Pha
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
52%Galunisertib + Nivolumab (NSCLC) P
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
45%300 mg BID + 200 mg Q3Wa
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
show 4 more results
50%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
51%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
40%50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
0%25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
a
vomiting 66.7%
dehydration 33.3%
depression 33.3%
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
show 5 more results
diarrhoea 40%
pulmonary embolism 40%
abdominal pain 20%
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
dyspnoea 33.3%
headache 33.3%
hyperglycaemia 33.3%
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
amylase increased 75%
aspartate aminotransferase increased 50%
blood alkaline phosphatase increased 50%
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
gingivitis 100%
rhinorrhoea 100%
abdominal distension 0%
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
pruritus 36%
decreased appetite 28%
diarrhoea 28%
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
300 mg BID + 200 mg Q3Wa
fatigue 65%
nausea 55%
vomiting 50%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
show 4 more results
100 mg BID + 200 mg Q3W
fatigue 50%
back pain 38.9%
diarrhoea 38.9%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 48.4%
nausea 30.1%
cough 26.2%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50 mg BID + 200 mg Q3W
fatigue 65%
arthralgia 45%
nausea 45%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
25 mg BID + 200 mg Q3W
arthralgia 100%
constipation 75%
cough 75%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Nivolumab

PFS 5.26 months
time to event · months
No placebo or comparator arm
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more result
5.39 months
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
ORR 24% (n=25)
responder rate · % of participants
No placebo or comparator arm
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more result
0% (n=1)
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
Duration of Response 9.03 months
time to event · months
No placebo or comparator arm
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
Time to Response 4.2 months
time to event · months
No placebo or comparator arm
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
Overall Survival 11.99 months
time to event · months
No placebo or comparator arm
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more result
14.52 months
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination

Gastric Cancer

Shared mechanism: PD-1 · full Gastric Cancer pipeline

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Gastric Cancermonoclonal antibody
Partial signal

NCT02872116 · Phase 3 · completed

The trial randomized 2,031 participants to nivolumab plus chemotherapy or active chemotherapy control, but treatment assignment was open-label rather than double-blinded. Its clinical primary endpoints were met, with statistically significant improvements in both overall survival and progression-free survival; however, the available record does not report a power calculation, so the evidence is graded moderate.

Next expected readout: December 2026 · NCT04900818 (registry estimate)

No aligned efficacy figure on record for this race.

Pembrolizumab

Marketed by Merck & Co.

Approved in Gastric Cancermonoclonal antibody
Reliable signal

NCT03615326 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled phase 3 trial; 698 participants were randomized in its main cohort, more than the approximately 692 its published sample-size calculation required. Both primary endpoints were met: progression-free survival by blinded central review (hazard ratio 0.73) and overall survival (hazard ratio 0.80) were significantly better with pembrolizumab.

Next expected readout: December 2026 · NCT05041153 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Gastric Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

Coverage. Nivolumab: 3 of 4 rows · Pembrolizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricNivolumabPembrolizumab
Dropout rate
0%0.009 mg/kg q3w + 360 mg q3wa
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
show 9 more results
0%0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
20%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
17.2%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
10.5%Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort A: Triple Negative Breast Ca
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
show 27 more results
n/a: no completion milestoneCohort B: Ovarian Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort C: Gastric Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort D1: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort D2: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneCohort E: Glioblastoma Multiforma
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort F: Biliary Tract Cancer (Le
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort G: Pancreatic Cancer (Lenva
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
25%Experimental: Expansion 1
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
0%Experimental: Expansion 2
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
4.8%Experimental: Expansion 3
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
0%Experimental: Safety Lead In
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1.6 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1.6 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
—0.009 mg/kg q3w + 360 mg q3wa
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
show 9 more results
—0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort A: Triple Negative Breast Ca
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
show 27 more results
—Cohort B: Ovarian Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Gastric Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort D1: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort D2: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence
—Cohort E: Glioblastoma Multiforma
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort F: Biliary Tract Cancer (Le
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort G: Pancreatic Cancer (Lenva
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Experimental: Expansion 1
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
—Experimental: Expansion 2
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
—Experimental: Expansion 3
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
—Experimental: Safety Lead In
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
1.6%100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
50%2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
66.7%1.6 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
0%1.6 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
66.7%0.009 mg/kg q3w + 360 mg q3wa
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
show 9 more results
50%0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
36%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
44.7%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
60%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
62.5%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
42.1%Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
51.6%Cohort A: Triple Negative Breast Ca
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
show 27 more results
61.3%Cohort B: Ovarian Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
57.6%Cohort C: Gastric Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
52.4%Cohort D1: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
40%Cohort D2: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence
29.7%Cohort E: Glioblastoma Multiforma
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
60.8%Cohort F: Biliary Tract Cancer (Le
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
47.6%Cohort G: Pancreatic Cancer (Lenva
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
66.7%Experimental: Expansion 1
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
60%Experimental: Expansion 2
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
35%Experimental: Expansion 3
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
16.7%Experimental: Safety Lead In
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
45%300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
51%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
40%50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
0%25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
38.2%100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
35.7%75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
37.5%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—1.6 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—1.6 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
0.009 mg/kg q3w + 360 mg q3wa
pyrexia 100%
rash 100%
chills 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
show 9 more results
0.006 mg/kg q3w + 240 mg q2w
arthralgia 100%
fatigue 100%
headache 100%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q2w + 240 mg q2w
chills 100%
pyrexia 100%
back pain 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 360 mg q3w
fatigue 76%
chills 64%
cough 60%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 360 mg q3w
fatigue 50.6%
pyrexia 47.9%
nausea 40.1%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.003 mg/kg q2w + 240 mg q2w
chills 100%
nasal congestion 100%
arthralgia 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 90%
diarrhoea 80%
nausea 80%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
diarrhoea 75%
influenza like illness 75%
pruritus 75%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
decreased appetite 100%
fatigue 100%
influenza like illness 100%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 78.9%
influenza like illness 68.4%
nausea 57.9%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
a
hypertension 51.6%
diarrhoea 45.2%
hypothyroidism 45.2%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
show 19 more results
hypertension 67.7%
diarrhoea 61.3%
decreased appetite 48.4%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 37.4%
nausea 31.3%
asthenia 30.3%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 56.2%
diarrhoea 44.8%
decreased appetite 43.8%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 56.7%
diarrhoea 53.3%
dysphonia 40%
NCT03797326 · Phase 2 · registry result, not featured evidence
hypertension 50.5%
asthenia 28.7%
hypothyroidism 27.7%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 56.9%
diarrhoea 41.2%
fatigue 39.2%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 53.4%
nausea 35.9%
decreased appetite 32%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
decreased appetite 50%
alanine aminotransferase increased 33.3%
diarrhea 33.3%
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
anaemia 80%
dizziness 80%
fatigue 80%
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
dizziness 45%
decreased appetite 30%
dyspnea 30%
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
abdominal pain 66.7%
blood alkaline phosphatase increased 66.7%
fatigue 66.7%
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
300 mg BID + 200 mg Q3W
fatigue 65%
nausea 55%
vomiting 50%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 50%
back pain 38.9%
diarrhoea 38.9%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 48.4%
nausea 30.1%
cough 26.2%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50 mg BID + 200 mg Q3W
fatigue 65%
arthralgia 45%
nausea 45%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
25 mg BID + 200 mg Q3W
arthralgia 100%
constipation 75%
cough 75%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg
diarrhoea 25.2%
constipation 23.6%
fatigue 23.6%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
75 mg
aspartate aminotransferase increased 21.4%
back pain 21.4%
fatigue 21.4%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
50 mg
fatigue 37.5%
diarrhoea 25%
decreased appetite 18.8%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Nivolumab

ORR 14.9% (n=429)0.006 mg/kg q3w + 360 mg q3w
event count · % of participants
No placebo or comparator arm
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 64 Participants as posted
show 1 more result
17.6% (n=17)*
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted

Pembrolizumab

Disease Control 47.6% (n=21)2.2 µg/kg
responder rate · % of participants
No placebo or comparator arm
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
show 11 more results
71.4% (n=14)2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
47.6% (n=21)2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
78.6% (n=14)2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
51.6% (n=31)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
77.4% (n=31)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
53.5% (n=99)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
52.4% (n=105)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
56.7% (n=30)
NCT03797326 · Phase 2 · registry result, not featured evidence
57.4% (n=101)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
64.7% (n=102)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
37.9% (n=103)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
Duration of Response 12.4 months100 mg
time to event · months
No placebo or comparator arm
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 14 more results
NA months75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
NA months50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
8.5 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
2.8 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
8.5 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
2.8 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
22.9 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
15.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
8.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
8.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT03797326 · Phase 2 · registry result, not featured evidence
4.6 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
6.2 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
5.8 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
PFS 2.1 months100 mg
time to event · months
No placebo or comparator arm
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 15 more results
3 months100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
2.6 months75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
2.1 months50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
1.4 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
4.2 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
1.4 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
4.2 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
4.2 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
6.1 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
3.5 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
3.4 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
3.4 months
NCT03797326 · Phase 2 · registry result, not featured evidence
3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
4.1 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
2.1 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
Overall Survival 4.4 months2.2 µg/kg
time to event · months
No placebo or comparator arm
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
show 9 more results
12.9 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
11.4 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
21.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
4.7 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
8.7 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
7.9 months
NCT03797326 · Phase 2 · registry result, not featured evidence
8.6 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
7.9 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
4.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
ORR 0% (n=10)100 mg
responder rate · % of participants
No placebo or comparator arm
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 5 more results
11% (n=118)100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
7.7% (n=13)75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
10% (n=10)50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
9.5% (n=21)2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
28.6% (n=14)2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
Complete 0% (n=10)100 mg
responder rate · % of participants
No placebo or comparator arm
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 3 more results
1.7% (n=118)100 mg
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0% (n=13)75 mg
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0% (n=10)50 mg
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Partial 0% (n=10)100 mg
responder rate · % of participants
No placebo or comparator arm
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 3 more results
9.3% (n=118)100 mg
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
7.7% (n=13)75 mg
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
10% (n=10)50 mg
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination

Melanoma

Shared mechanism: PD-1 · full Melanoma pipeline

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Melanomamonoclonal antibody
Partial signal

NCT01721746 · Phase 3 · completed

This was a large randomized trial against chemotherapy, but it was open-label. Overall survival, an objective outcome, was not significantly better with nivolumab, although more patients had a tumour response.

Next expected readout: November 2026 · NCT06712927 (registry estimate)

Reported efficacy

Recurrence-free Survival (RFS) (up to 36 months): Recurrence-free Survival (RFS) (up to 36 months): Nivolumab 3 mg/kg 52.37 Months | Ipilimumab 10 mg/kg 24.08 Months (95% CI 16.56 to 35.09) (met)

Result source: NCT02388906

Pembrolizumab

Marketed by Merck & Co.

Approved in Melanomamonoclonal antibody
Partial signal

NCT01866319 · Phase 3 · completed

The trial randomized 834 participants to two pembrolizumab schedules or active-control ipilimumab, with progression assessed by blinded independent radiology review and statistically significant improvements in progression-free survival and overall survival for both pembrolizumab schedules versus ipilimumab. However, treatment assignment was open-label rather than double-blinded, so the evidence is rated moderate despite the objective clinical endpoints and favorable results.

Next expected readout: December 2026 · NCT02644369 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Melanoma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Nivolumab: 9 of 10 rows · Pembrolizumab: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricNivolumab
Rows use multiple source trials
Pembrolizumab
Rows use multiple source trials
Duration of Response
time to event · months
No placebo or comparator arm
NA months30 mga,b,c
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more doses
7.38 months*30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 32 weeks as posted
20.63 months*30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 89.4 weeks as posted
15.61 months5 mg weeklya,b,c
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
show 6 more doses
NA months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
10.1 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
10.14 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
25.49 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
25.49 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
7.33 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
ORR
event count · % of participants
No placebo or comparator arm
14.9% (n=429)*0.006 mg/kg q3w + 360 mg q3wa,d,b,c
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 64 Participants as posted
show 1 more dose
17.6% (n=17)*
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
20% (n=5)*3.2/4 mga,d,b,c
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
show 19 more doses
20% (n=5)*3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
6.3% (n=95)*1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 6 Participants as posted
10.7% (n=28)*1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
39.6% (n=48)*1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 19 Participants as posted
0% (n=5)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted
46.7% (n=15)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
0% (n=6)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
16.7% (n=6)*0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
20% (n=5)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
35.7% (n=14)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted
100% (n=1)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
0% (n=5)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
0% (n=6)*0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted
33.3% (n=3)*0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
20% (n=5)*0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
0% (n=4)*0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
0% (n=5)*0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted
25% (n=4)*0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
0% (n=4)*0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted
ORR
responder rate · % of participants
No placebo or comparator arm
0% (n=1)400 mga,b,c
NCT02658890 · Phase 1/2 · registry result, not featured evidence
show 15 more doses
0% (n=6)BMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
5.6% (n=18)BMS-986205 200 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
31.3% (n=16)BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
23.5% (n=17)BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
28.6% (n=14)BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0% (n=12)BMS-986205 100 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
42.9% (n=14)BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0% (n=18)BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
13.3% (n=15)BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0% (n=1)50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
10% (n=10)BMS-986205 50 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0% (n=7)BMS-986205 25 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
14.3% (n=14)
NCT02658890 · Phase 1/2 · registry result, not featured evidence
11.8% (n=17)
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
50% (n=6)
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
22.2% (n=18)5 mg weeklya,b,c
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
show 3 more doses
9.2% (n=76)5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
18.9% (n=53)5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5.4% (n=37)5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
PFS
time to event · months
No placebo or comparator arm
2 monthsa,e,b,c
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
2 months
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
2.76 months5 mg weeklya,e,b,c
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
show 7 more doses
2.76 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.83 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.69 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
4.4 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.96 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
1.91 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
1.91 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
Progressive Disease
event count · % of participants
No placebo or comparator arm
Progressive disease (PD)
0% (n=1)*400 mga,f,c
NCT02658890 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 15 more doses
66.7% (n=6)*BMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 4 Participants as posted
50% (n=18)*BMS-986205 200 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 9 Participants as posted
37.5% (n=16)*BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 6 Participants as posted
17.6% (n=17)*BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
14.3% (n=14)*BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
58.3% (n=12)*BMS-986205 100 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
57.1% (n=14)*BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 8 Participants as posted
55.6% (n=18)*BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 10 Participants as posted
20% (n=15)*BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
0% (n=1)*50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 Participants as posted
50% (n=10)*BMS-986205 50 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted
71.4% (n=7)*BMS-986205 25 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted
50% (n=14)*
NCT02658890 · Phase 1/2 · registry result, not featured evidence · converted to % from 7 Participants as posted
52.9% (n=17)*
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 9 Participants as posted
33.3% (n=6)*
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
50% (n=10) @ 52wk*a,f,c
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted
show 1 more dose
20% (n=5) @ 52wk*
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
Stable Disease
event count · % of participants
No placebo or comparator arm
Stable disease (SD)
0% (n=1)*400 mga,f,c
NCT02658890 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 15 more doses
33.3% (n=6)*BMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
22.2% (n=18)*BMS-986205 200 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 4 Participants as posted
25% (n=16)*BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 4 Participants as posted
47.1% (n=17)*BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 8 Participants as posted
28.6% (n=14)*BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 4 Participants as posted
33.3% (n=12)*BMS-986205 100 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 4 Participants as posted
0% (n=14)*BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
33.3% (n=18)*BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 6 Participants as posted
40% (n=15)*BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 6 Participants as posted
0% (n=1)*50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 Participants as posted
30% (n=10)*BMS-986205 50 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
28.6% (n=7)*BMS-986205 25 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
21.4% (n=14)*
NCT02658890 · Phase 1/2 · registry result, not featured evidence · converted to % from 3 Participants as posted
17.6% (n=17)*
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
16.7% (n=6)*
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
40% (n=10) @ 52wk*a,f,c
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 4 Participants as posted
show 1 more dose
40% (n=5) @ 52wk*
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
Dropout rate
—Pixatimod (PG545) + Nivolumab + Cyg
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 66 more results
0%Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
100%40 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
100%30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
97.5%30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
100%20 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
0%0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
20%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
17.2%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
10.5%Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—400 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
—BMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 200 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 100 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
0%BMS-986205 50 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
0%BMS-986205 25 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%Food Effect/ Relative BA (FE BA) S
NCT02658890 · Phase 1/2 · registry result, not featured evidence
0%Part 2: Exp ML Anti-PDL1+CTLA4
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 2: Exp ML BRAF-MT- NIVO
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—0.3 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—0.1 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—0.03 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 1(Arm)/ inNSCLC (Phase 2) -
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 2(Arm)/ PD1-MM (Phase 2) -
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 3A(Arm)/ PD1-NSCLC (Phase 2
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 3B(Arm)/ PD1-NSCLC (Phase 2
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
100%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
99.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
96.5%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
85.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
0%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
89.3%200 mg IV Q3Wg
NCT03715205 · Phase 4 · registry result, not featured evidence
show 59 more results
0%Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
50%Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
0%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
0%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
66.7%3 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
0%Phase 1: Lung Targets + MK-3475 /
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
0%Phase 1: Non-Lung Target + MK-3475
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
0%30 Gy over 5 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
0%27 Gy over 3 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
0%18-21 Gy in one fraction
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
100%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
99.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
96.5%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
85.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
0%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
57.1%20 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
—12.5 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
92.3%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
92.5%10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
91.6%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
93.2%10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
100%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
100%3 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
89%2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
90.2%2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
100%1 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
100%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
66.7%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
100%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—Pixatimod (PG545) + Nivolumab + Cyg
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 66 more results
—Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
—40 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
—30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
—30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
—20 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
—0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—400 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
—BMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 200 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 100 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
—BMS-986205 50 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
—BMS-986205 25 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—Food Effect/ Relative BA (FE BA) S
NCT02658890 · Phase 1/2 · registry result, not featured evidence
—Part 2: Exp ML Anti-PDL1+CTLA4
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2: Exp ML BRAF-MT- NIVO
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—0.3 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—0.1 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—0.03 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 1(Arm)/ inNSCLC (Phase 2) -
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 2(Arm)/ PD1-MM (Phase 2) -
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 3A(Arm)/ PD1-NSCLC (Phase 2
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 3B(Arm)/ PD1-NSCLC (Phase 2
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—200 mg IV Q3Wg
NCT03715205 · Phase 4 · registry result, not featured evidence
show 59 more results
—Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
—Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—3 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 1: Lung Targets + MK-3475 /
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 1: Non-Lung Target + MK-3475
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
—30 Gy over 5 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
—27 Gy over 3 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
—18-21 Gy in one fraction
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
—3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—20 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
—12.5 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
12%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
15.3%10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
10.3%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
16.9%10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
16.7%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
66.7%3 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
9.1%2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
11.5%2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
25%1 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
25%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
33.3%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
66.7%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
Serious AEs
37.5%Pixatimod (PG545) + Nivolumab + Cyg
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 66 more results
20%Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
57.1%40 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
85.7%30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
49.4%30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
33.3%20 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
66.7%0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
50%0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
36%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
44.7%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
60%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
62.5%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
42.1%Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
100%400 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
83.3%BMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
66.7%BMS-986205 200 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
68.8%BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
82.4%BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
64.3%BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
66.7%BMS-986205 100 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
85.7%BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
83.3%BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
80%BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
100%50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
60%BMS-986205 50 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
71.4%BMS-986205 25 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
50%Food Effect/ Relative BA (FE BA) S
NCT02658890 · Phase 1/2 · registry result, not featured evidence
58.8%Part 2: Exp ML Anti-PDL1+CTLA4
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
16.7%Part 2: Exp ML BRAF-MT- NIVO
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%0.3 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.1 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.03 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
47.2%Cohort 1(Arm)/ inNSCLC (Phase 2) -
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
15.8%Cohort 2(Arm)/ PD1-MM (Phase 2) -
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
42.9%Cohort 3A(Arm)/ PD1-NSCLC (Phase 2
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
46.4%Cohort 3B(Arm)/ PD1-NSCLC (Phase 2
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
40%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
60%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
51.3%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
47.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
56.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
55.6%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
66.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
66.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
16.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
57.1%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
20%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
40%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
0%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
75%0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
14.3%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
66.7%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
100%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
20.7%200 mg IV Q3Wg
NCT03715205 · Phase 4 · registry result, not featured evidence
show 59 more results
10.8%Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
20%Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
22.2%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
57.1%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
55.6%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
43.4%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
45.3%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
36.8%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
66.7%3 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
45%300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
51%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
40%50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
0%25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50%Phase 1: Lung Targets + MK-3475 /
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
20%Phase 1: Non-Lung Target + MK-3475
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
33.3%30 Gy over 5 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
41.7%27 Gy over 3 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
14.3%18-21 Gy in one fraction
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
40%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
60%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
51.3%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
47.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
56.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
55.6%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
66.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
66.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
16.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
57.1%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
20%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
40%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
0%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
75%0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
14.3%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
66.7%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
100%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
14.3%20 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
—12.5 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
43.9%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
41.2%10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
42.6%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
41.5%10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
30%10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
33.3%3 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
42.6%2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
55.7%2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
25%1 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
0%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
66.7%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
33.3%Solid Tumors: Pembrolizumab Titrat
NCT01295827 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
g
anemia 62.5%
fatigue 50%
hyponatremia 50%
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 63 more results
activated partial thromboplastin time prolonged 80%
hypertriglyceridemia 60%
hyponatremia 60%
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
40 mg
anaemia 57.1%
decreased appetite 57.1%
contusion 42.9%
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
30 mg
fatigue 71.4%
weight decreased 71.4%
anaemia 57.1%
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
30 mg
fatigue 65.8%
nausea 55.7%
diarrhoea 53.2%
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
20 mg
diarrhoea 66.7%
dyspnoea 66.7%
fatigue 66.7%
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
0.009 mg/kg q3w + 360 mg q3w
pyrexia 100%
rash 100%
chills 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 240 mg q2w
arthralgia 100%
fatigue 100%
headache 100%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q2w + 240 mg q2w
chills 100%
pyrexia 100%
back pain 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 360 mg q3w
fatigue 76%
chills 64%
cough 60%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 360 mg q3w
fatigue 50.6%
pyrexia 47.9%
nausea 40.1%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.003 mg/kg q2w + 240 mg q2w
chills 100%
nasal congestion 100%
arthralgia 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 90%
diarrhoea 80%
nausea 80%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
diarrhoea 75%
influenza like illness 75%
pruritus 75%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
decreased appetite 100%
fatigue 100%
influenza like illness 100%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 78.9%
influenza like illness 68.4%
nausea 57.9%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
400 mg
abdominal discomfort 0%
abdominal distension 0%
abdominal hernia 0%
NCT02658890 · Phase 1/2 · registry result, not featured evidence
BMS-986205 400 mg + nivolumab 240 mg
constipation 66.7%
fatigue 66.7%
vomiting 66.7%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 200 mg + nivolumab 240 mg
fatigue 66.7%
nausea 44.4%
vomiting 44.4%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 200 mg
decreased appetite 43.8%
fatigue 43.8%
nausea 43.8%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 200 mg
fatigue 52.9%
alanine aminotransferase increased 35.3%
urinary tract infection 35.3%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 200 mg
fatigue 42.9%
constipation 28.6%
nausea 28.6%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 100 mg + nivolumab 240 mg
fatigue 58.3%
anaemia 50%
decreased appetite 50%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 100 mg
asthenia 28.6%
decreased appetite 28.6%
nausea 28.6%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 100 mg
decreased appetite 55.6%
nausea 50%
vomiting 38.9%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 100 mg
decreased appetite 33.3%
asthenia 26.7%
constipation 26.7%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
50 mg
headache 100%
oedema peripheral 100%
vomiting 100%
NCT02658890 · Phase 1/2 · registry result, not featured evidence
BMS-986205 50 mg + nivolumab 240 mg
fatigue 70%
vomiting 60%
decreased appetite 50%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
50 mg
abdominal discomfort 0%
abdominal distension 0%
abdominal hernia 0%
NCT02658890 · Phase 1/2 · registry result, not featured evidence
BMS-986205 25 mg + nivolumab 240 mg
fatigue 57.1%
nausea 57.1%
vomiting 57.1%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 64.3%
nausea 42.9%
diarrhoea 35.7%
NCT02658890 · Phase 1/2 · registry result, not featured evidence
constipation 29.4%
fatigue 29.4%
nausea 29.4%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
diarrhoea 50%
fatigue 50%
headache 50%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0.3 mg/kg + Nivolumab
chills 100%
nausea 100%
pruritus 100%
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
0.1 mg/kg + Nivolumab
anaemia 66.7%
chills 66.7%
decreased appetite 66.7%
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
0.03 mg/kg + Nivolumab
fatigue 100%
anxiety 33.3%
arthralgia 33.3%
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
chills 56.6%
pyrexia 52.8%
nausea 45.3%
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
pyrexia 68.4%
chills 50%
nausea 47.4%
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
nausea 50%
pyrexia 50%
dyspnoea 42.9%
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
chills 46.4%
asthenia 42.9%
pyrexia 42.9%
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
3.2/4 mg
anaemia 80%
decreased appetite 80%
fatigue 80%
NCT02009449 · Phase 1 · registry result, not featured evidence
3.2/4 mg
fatigue 100%
anaemia 80%
headache 60%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
1.6/2 mg
anaemia 75.2%
fatigue 59%
thrombocytopenia 59%
NCT02009449 · Phase 1 · registry result, not featured evidence
1.6/2 mg
fatigue 85.3%
anaemia 76.5%
thrombocytopenia 58.8%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
1.6/2 mg
anaemia 68.4%
fatigue 59.6%
cough 42.1%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
constipation 66.7%
decreased appetite 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.8/1 mg
fatigue 88.9%
nausea 83.3%
anaemia 77.8%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
thrombocytopenia 66.7%
fatigue 50%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
fatigue 66.7%
thrombocytopenia 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
fatigue 100%
decreased appetite 66.7%
lipase increased 50%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
fatigue 85.7%
thrombocytopenia 71.4%
anaemia 57.1%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
activated partial thromboplastin time prolonged 100%
alanine aminotransferase increased 100%
anaemia 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 100%
fatigue 100%
thrombocytopenia 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
anaemia 83.3%
fatigue 83.3%
nausea 83.3%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.4/0.5 mg
anaemia 100%
dyspnoea 66.7%
fatigue 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
thrombocytopenia 100%
fatigue 66.7%
anaemia 33.3%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
fatigue 100%
anaemia 80%
hypokalaemia 60%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.2/0.25 mg
anaemia 50%
fatigue 50%
injection site erythema 50%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.2/0.25 mg
asthenia 100%
neutropenia 100%
spermatic cord disorder 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.08/0.1 mg
injection site erythema 75%
abdominal distension 50%
abdominal pain 50%
NCT02009449 · Phase 1 · registry result, not featured evidence
280 mg PO BID
aspartate aminotransferase increased 14.3%
cough 14.3%
fatigue 14.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg / 280 mg
anemia 66.7%
back pain 66.7%
diarrhea 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO BID
lipase increased 66.7%
alkaline phosphatase increased 33.3%
anorexia 33.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO daily
hepatobiliary disorders - other, specify 100%
abdominal pain 66.7%
back pain 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
200 mg IV Q3Wg
hypothyroidism 17.3%
anaemia 12.7%
constipation 11.3%
NCT03715205 · Phase 4 · registry result, not featured evidence
show 56 more results
headache 40.5%
fatigue 24.3%
rash 21.6%
NCT02681549 · Phase 2 · registry result, not featured evidence
anorexia 40%
gastrointestinal disorders - other, specify 40%
hypertension 40%
NCT02681549 · Phase 2 · registry result, not featured evidence
5 mg weekly
fatigue 66.7%
decreased appetite 55.6%
cough 33.3%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
fatigue 85.7%
cough 42.9%
hypophosphataemia 42.9%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
fatigue 77.8%
musculoskeletal and connective tissue disorders 55.6%
cough 38.9%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
fatigue 47.4%
musculoskeletal and connective tissue disorders 44.7%
decreased appetite 35.5%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
nausea 56.6%
fatigue 54.7%
musculoskeletal and connective tissue disorders 45.3%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
fatigue 57.9%
musculoskeletal and connective tissue disorders 44.7%
blood alkaline phosphatase increased 36.8%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
3 mg weekly
decreased appetite 50%
cough 33.3%
diarrhoea 33.3%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
300 mg BID + 200 mg Q3W
fatigue 65%
nausea 55%
vomiting 50%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 50%
back pain 38.9%
diarrhoea 38.9%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 48.4%
nausea 30.1%
cough 26.2%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50 mg BID + 200 mg Q3W
fatigue 65%
arthralgia 45%
nausea 45%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
25 mg BID + 200 mg Q3W
arthralgia 100%
constipation 75%
cough 75%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
dyspnea 90%
fatigue 90%
pain 70%
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 100%
cough 80%
pain 60%
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination
30 Gy over 5 fractions
headache 33.3%
agitation 16.7%
dermatitis, other 16.7%
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
27 Gy over 3 fractions
symptomatic radionecrosis 16.7%
constipation 8.3%
dermatitis, other 8.3%
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
18-21 Gy in one fraction
symptomatic radionecrosis 14.3%
agitation 0%
constipation 0%
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
3.2/4 mg
anaemia 80%
decreased appetite 80%
fatigue 80%
NCT02009449 · Phase 1 · registry result, not featured evidence
3.2/4 mg
fatigue 100%
anaemia 80%
headache 60%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
1.6/2 mg
anaemia 75.2%
fatigue 59%
thrombocytopenia 59%
NCT02009449 · Phase 1 · registry result, not featured evidence
1.6/2 mg
fatigue 85.3%
anaemia 76.5%
thrombocytopenia 58.8%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
1.6/2 mg
anaemia 68.4%
fatigue 59.6%
cough 42.1%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
constipation 66.7%
decreased appetite 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.8/1 mg
fatigue 88.9%
nausea 83.3%
anaemia 77.8%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
thrombocytopenia 66.7%
fatigue 50%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
fatigue 66.7%
thrombocytopenia 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
fatigue 100%
decreased appetite 66.7%
lipase increased 50%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
fatigue 85.7%
thrombocytopenia 71.4%
anaemia 57.1%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
activated partial thromboplastin time prolonged 100%
alanine aminotransferase increased 100%
anaemia 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 100%
fatigue 100%
thrombocytopenia 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
anaemia 83.3%
fatigue 83.3%
nausea 83.3%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.4/0.5 mg
anaemia 100%
dyspnoea 66.7%
fatigue 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
thrombocytopenia 100%
fatigue 66.7%
anaemia 33.3%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
fatigue 100%
anaemia 80%
hypokalaemia 60%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.2/0.25 mg
anaemia 50%
fatigue 50%
injection site erythema 50%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.2/0.25 mg
asthenia 100%
neutropenia 100%
spermatic cord disorder 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.08/0.1 mg
injection site erythema 75%
abdominal distension 50%
abdominal pain 50%
NCT02009449 · Phase 1 · registry result, not featured evidence
280 mg PO BID
aspartate aminotransferase increased 14.3%
cough 14.3%
fatigue 14.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg / 280 mg
anemia 66.7%
back pain 66.7%
diarrhea 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO BID
lipase increased 66.7%
alkaline phosphatase increased 33.3%
anorexia 33.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO daily
hepatobiliary disorders - other, specify 100%
abdominal pain 66.7%
back pain 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
20 mg/kg
hypertension 28.6%
anemia 14.3%
arthralgia 14.3%
NCT03236935 · Phase 1 · registry result, not featured evidence
10 mg/kg Q2W
fatigue 58.9%
diarrhoea 38.9%
nausea 38.3%
NCT01295827 · Phase 1 · registry result, not featured evidence
10 mg/kg Q3W
fatigue 52.1%
diarrhoea 35.5%
nausea 34.5%
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
10 mg/kg Q2W
fatigue 38.6%
decreased appetite 27.2%
dyspnoea 25.7%
NCT01295827 · Phase 1 · registry result, not featured evidence
10 mg/kg Q3W
fatigue 42.5%
decreased appetite 30.7%
cough 30%
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
10 mg/kg Q2W
fatigue 50%
decreased appetite 30%
constipation 20%
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
3 mg/kg Q2W
back pain 66.7%
nausea 66.7%
breast pain 33.3%
NCT01295827 · Phase 1 · registry result, not featured evidence
2 mg/kg Q3W
fatigue 47.5%
nausea 34.6%
diarrhoea 33.3%
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
2 mg/kg Q3W
fatigue 27.9%
diarrhoea 19.7%
constipation 16.4%
NCT01295827 · Phase 1 · registry result, not featured evidence
1 mg/kg Q2W
pruritus 75%
abdominal pain upper 25%
anaemia 25%
NCT01295827 · Phase 1 · registry result, not featured evidence
bradycardia 25%
diarrhoea 25%
fatigue 25%
NCT01295827 · Phase 1 · registry result, not featured evidence
diarrhoea 66.7%
fatigue 66.7%
pruritus 66.7%
NCT01295827 · Phase 1 · registry result, not featured evidence
decreased appetite 66.7%
fatigue 50%
depression 33.3%
NCT01295827 · Phase 1 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation context differs: registered conditions differ.
  3. cThe assessment timepoint is not available for both results.
  4. dTrial phases differ: Phase 1 versus Phase 1/2.
  5. eTrial phases differ: Phase 1/2 versus Phase 2.
  6. fPopulation comparability has not been reviewed for both studies.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Nivolumab

Stable Disease 40% (n=5)
absolute value · percentage points
No placebo or comparator arm
Stable Disease (SD)
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
37.5% (n=8)
Stable Disease (SD)
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
Progressive Disease 60% (n=5)
absolute value · percentage points
No placebo or comparator arm
Progressive Disease (PD)
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
62.5% (n=8)
Progressive Disease (PD)
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
PFS 6mo 20% (n=5) @ 24wk
absolute value · percentage points
No placebo or comparator arm
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
13% (n=8) @ 24wk
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
PFS 12mo 0% (n=5) @ 52wk
absolute value · percentage points
No placebo or comparator arm
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
13% (n=8) @ 52wk
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
PFS 24 0% (n=5) @ 104wk
absolute value · percentage points
No placebo or comparator arm
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0% (n=8) @ 104wk
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
OS 6mo 75% (n=5) @ 24wk
absolute value · percentage points
No placebo or comparator arm
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
50% (n=8) @ 24wk
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
OS Rate at 12 0% (n=5) @ 52wk
absolute value · percentage points
No placebo or comparator arm
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
19% (n=8) @ 52wk
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
OS24 0% (n=5) @ 104wk
absolute value · percentage points
No placebo or comparator arm
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0% (n=8) @ 104wk
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
ORR 56.6% (n=53)30 mg
absolute value · percentage points
No placebo or comparator arm
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
22.7% (n=22)30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
16.7% (n=6)30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
Disease Control 84.9% (n=53)30 mg
absolute value · percentage points
No placebo or comparator arm
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
68.2% (n=22)30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
66.7% (n=6)30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
PFS 6mo NA @ 24wk400 mg
responder rate · % of participants
No placebo or comparator arm
NCT02658890 · Phase 1/2 · registry result, not featured evidence
show 19 more results
NA @ 24wkBMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
38% (n=17) @ 24wkBMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
42.9% (n=14) @ 24wkBMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
37.5% (n=16) @ 24wkBMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
28.2% (n=18) @ 24wkBMS-986205 200 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
6.6% (n=18) @ 24wkBMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
20% (n=15) @ 24wkBMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
42.9% (n=14) @ 24wkBMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
30.7% (n=12) @ 24wkBMS-986205 100 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
NA @ 24wk50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
30% (n=10) @ 24wkBMS-986205 50 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
14.3% (n=7) @ 24wkBMS-986205 25 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
50% (n=6) @ 24wk
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
17.6% (n=17) @ 24wk
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
35.7% (n=14) @ 24wk
NCT02658890 · Phase 1/2 · registry result, not featured evidence
33.1% (n=48) @ 26wk
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
21.21% (n=33) @ 26wk
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
25% (n=12) @ 26wk
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
12.92% (n=25) @ 26wk
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
PFS-12 NA @ 52wk400 mg
responder rate · % of participants
No placebo or comparator arm
NCT02658890 · Phase 1/2 · registry result, not featured evidence
show 15 more results
NA @ 52wkBMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
19% (n=17) @ 52wkBMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
34.3% (n=14) @ 52wkBMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
31.3% (n=16) @ 52wkBMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
21.2% (n=18) @ 52wkBMS-986205 200 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
NA @ 52wkBMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
13.3% (n=15) @ 52wkBMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
28.6% (n=14) @ 52wkBMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
NA @ 52wkBMS-986205 100 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
NA @ 52wk50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
15% (n=10) @ 52wkBMS-986205 50 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
NA @ 52wkBMS-986205 25 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
50% (n=6) @ 52wk
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
11.8% (n=17) @ 52wk
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
14.3% (n=14) @ 52wk
NCT02658890 · Phase 1/2 · registry result, not featured evidence

+ 1 further endpoint in the CSV export.

Pembrolizumab

Brain Metastasis 54.1% (n=37)
responder rate · % of participants
No placebo or comparator arm
NCT02681549 · Phase 2 · registry result, not featured evidence
show 1 more result
75% (n=4)
NCT02681549 · Phase 2 · registry result, not featured evidence
Intracranial ORR 54.1% (n=37)
responder rate · % of participants
No placebo or comparator arm
Intracranial
NCT02681549 · Phase 2 · registry result, not featured evidence
show 1 more result
75% (n=4)
Intracranial
NCT02681549 · Phase 2 · registry result, not featured evidence
Extracranial 56.3% (n=37)
responder rate · % of participants
No placebo or comparator arm
Extracranial
NCT02681549 · Phase 2 · registry result, not featured evidence
show 1 more result
75% (n=4)
Extracranial
NCT02681549 · Phase 2 · registry result, not featured evidence
PFS 14.4 months
time to event · months
No placebo or comparator arm
Median overall PFS
NCT02681549 · Phase 2 · registry result, not featured evidence · converted to months from 1.2 years as posted
show 1 more result
NA months
Median overall PFS
NCT02681549 · Phase 2 · registry result, not featured evidence
Clinical Benefit 33.3% (n=18) @ 24wk5 mg weekly
responder rate · % of participants
No placebo or comparator arm
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
show 7 more results
14.5% (n=76) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
35.8% (n=53) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
8.1% (n=37) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
22.2% (n=18) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
14.5% (n=76) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
30.2% (n=53) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.7% (n=37) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
PFS 6mo 16.7% (n=18) @ 24wk5 mg weekly
event count · % of participants
No placebo or comparator arm
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
show 7 more results
22.4% (n=76) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
37.7% (n=53) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 20 Participants as posted
8.1% (n=37) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
16.7% (n=18) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
22.4% (n=76) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
32.1% (n=53) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
5.4% (n=37) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
Overall Survival 22.5 months10 mg/kg Q3W
time to event · months
No placebo or comparator arm
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
show 12 more results
26.8 months10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
13.1 months10 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
13.4 months10 mg/kg Q2W
NCT01295827 · Phase 1 · registry result, not featured evidence
25.2 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
11.73 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
12.52 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
9.79 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
23.1 months2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence · combination
8.9 months2 mg/kg Q3W
NCT01295827 · Phase 1 · registry result, not featured evidence
NA months30 Gy over 5 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
32.8 months27 Gy over 3 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
12.2 months18-21 Gy in one fraction
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
Time to Response 4.3 months5 mg weekly
time to event · months
No placebo or comparator arm
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
show 6 more results
2.83 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
1.95 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
4.17 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
4.29 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.83 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
1.95 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
Complete 0% (n=10) @ 52wk
responder rate · % of participants
No placebo or comparator arm
Complete response (CR)
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
show 1 more result
0% (n=5) @ 52wk*
Complete response (CR)
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
Partial 10% (n=10) @ 52wk
responder rate · % of participants
No placebo or comparator arm
Partial response (PR)
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
show 1 more result
0% (n=5) @ 52wk*
Partial response (PR)
NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
Intracranial Clinical Benefit 100% (n=5) @ 24wk30 Gy over 5 fractions
responder rate · % of participants
No placebo or comparator arm
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
show 2 more results
60% (n=10) @ 24wk27 Gy over 3 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
20% (n=5) @ 24wk18-21 Gy in one fraction
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
Extra-cranial Clinical Benefit 60% (n=5) @ 24wk30 Gy over 5 fractions
responder rate · % of participants
No placebo or comparator arm
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
show 2 more results
55% (n=11) @ 24wk27 Gy over 3 fractions
NCT02858869 · Phase 1 · registry result, not featured evidence · combination
33% (n=6) @ 24wk18-21 Gy in one fraction
NCT02858869 · Phase 1 · registry result, not featured evidence · combination

+ 1 further endpoint in the CSV export.

Colorectal Cancer

Shared mechanism: PD-1 · full Colorectal Cancer pipeline

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Colorectal Cancermonoclonal antibody
Weak signal

NCT02060188 · Phase 2 · completed

The study was non-randomized, unblinded, and had no comparator arm; its 385 participants were distributed across multiple treatment cohorts, including small cohorts. The primary endpoint was investigator-assessed tumor response, and although results were posted, there was no controlled primary comparison to determine whether nivolumab improved outcomes.

Next expected readout: December 2026 · NCT04912765 (registry estimate)

No aligned efficacy figure on record for this race.

Pembrolizumab

Marketed by Merck & Co.

Approved in Colorectal Cancermonoclonal antibody
Weak signal

NCT02460198 · Phase 2 · completed

The study treated 124 participants with pembrolizumab in a non-randomized, open-label, single-group design without a placebo or active comparator. Although the primary endpoint was an objective tumor response measure assessed by central imaging, the study had no formal between-group comparison and therefore provides limited evidence of pembrolizumab’s comparative benefit.

Next expected readout: December 2026 · NCT05784688 (registry estimate)

Reported efficacy

Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48) (not_applicable)

Result source: NCT02460198

Results for Colorectal Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Nivolumab: registry results are on file for Colorectal Cancer, but their comparison mappings are not yet available.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Pembrolizumab

Disease Control 51.6% (n=31)
responder rate · % of participants
No placebo or comparator arm
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
show 7 more results
77.4% (n=31)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
53.5% (n=99)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
52.4% (n=105)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
56.7% (n=30)
NCT03797326 · Phase 2 · registry result, not featured evidence
57.4% (n=101)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
64.7% (n=102)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
37.9% (n=103)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
Duration of Response 12.4 months100 mg
time to event · months
No placebo or comparator arm
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 17 more results
NA months75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
NA months50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
15.61 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
10.1 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
25.49 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
7.33 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
NA months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
10.14 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
25.49 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
22.9 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
15.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
8.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
8.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT03797326 · Phase 2 · registry result, not featured evidence
4.6 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
6.2 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
5.8 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
PFS 2.1 months100 mg
time to event · months
No placebo or comparator arm
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 19 more results
3 months100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
2.6 months75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
2.1 months50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
2.76 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.83 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
4.4 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
1.91 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.76 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.69 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.96 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
1.91 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
4.2 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
6.1 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
3.5 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
3.4 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
3.4 months
NCT03797326 · Phase 2 · registry result, not featured evidence
3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
4.1 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
2.1 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
Overall Survival NA months1200 ug/kg
time to event · months
No placebo or comparator arm
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
show 22 more results
9.4 months960 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
NA months480 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
25.2 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
11.73 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
12.52 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
9.79 months5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
11.4 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
21.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
4.7 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
8.7 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
7.9 months
NCT03797326 · Phase 2 · registry result, not featured evidence
8.6 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
7.9 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
4.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
9.1 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
17.3 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
5.9 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
9.3 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
16 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
11.1 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
6.7 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
10.1 months
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
ORR 0% (n=14)
responder rate · % of participants
No placebo or comparator arm
ORR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
show 7 more results
0% (n=26)
ORR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
13.3% (n=15)
ORR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
3.7% (n=27)
ORR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
0% (n=26)
ORR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
3.8% (n=26)
ORR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
3.8% (n=26)
ORR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
16.7% (n=12)
ORR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
Immune ORR 0% (n=14)
responder rate · % of participants
No placebo or comparator arm
ORR per iRECIST
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
show 7 more results
3.8% (n=26)
ORR per iRECIST
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
13.3% (n=15)
ORR per iRECIST
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
11.1% (n=27)
ORR per iRECIST
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
0% (n=26)
ORR per iRECIST
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
7.7% (n=26)
ORR per iRECIST
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
3.8% (n=26)
ORR per iRECIST
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
16.7% (n=12)
ORR per iRECIST
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
Duration of Response NA months480 ug/kg
time to event · months
No placebo or comparator arm
DOR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
show 5 more results
NA months
DOR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
13.1 months
DOR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
NA months
DOR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
8.6 months
DOR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
NA months
DOR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
Disease Control 66.7% (n=6)1200 ug/kg
responder rate · % of participants
No placebo or comparator arm
DCR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
show 10 more results
0% (n=3)960 ug/kg
DCR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
66.7% (n=3)480 ug/kg
DCR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
21.4% (n=14)
DCR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
42.3% (n=26)
DCR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
20% (n=15)
DCR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
40.7% (n=27)
DCR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
30.8% (n=26)
DCR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
30.8% (n=26)
DCR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
19.2% (n=26)
DCR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
25% (n=12)
DCR per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
PFS 5.3 months1200 ug/kg
time to event · months
No placebo or comparator arm
PFS per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
show 10 more results
1.3 months960 ug/kg
PFS per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
8.6 months480 ug/kg
PFS per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
1.2 months
PFS per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
1.4 months
PFS per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
1.3 months
PFS per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
1.7 months
PFS per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
1.4 months
PFS per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
1.4 months
PFS per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
1.3 months
PFS per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
1.4 months
PFS per RECIST 1.1
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
ORR 0% (n=10)100 mg
responder rate · % of participants
No placebo or comparator arm
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 7 more results
11% (n=118)100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
7.7% (n=13)75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
10% (n=10)50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
22.2% (n=18)5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
9.2% (n=76)5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
18.9% (n=53)5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5.4% (n=37)5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
Clinical Benefit 33.3% (n=18) @ 24wk5 mg weekly
responder rate · % of participants
No placebo or comparator arm
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
show 7 more results
14.5% (n=76) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
35.8% (n=53) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
8.1% (n=37) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
22.2% (n=18) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
14.5% (n=76) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
30.2% (n=53) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
2.7% (n=37) @ 24wk5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
PFS 6mo 16.7% (n=18) @ 24wk5 mg weekly
event count · % of participants
No placebo or comparator arm
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
show 7 more results
22.4% (n=76) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
37.7% (n=53) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 20 Participants as posted
8.1% (n=37) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
16.7% (n=18) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
22.4% (n=76) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
32.1% (n=53) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
5.4% (n=37) @ 24wk*5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted

+ 6 further endpoints in the CSV export.

Available safety results

Pembrolizumab

Dropout rate
n/a: no completion milestoneCohort A: Triple Negative Breast C
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
show 44 more results
n/a: no completion milestoneCohort B: Ovarian Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort C: Gastric Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort D1: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort D2: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneCohort E: Glioblastoma Multiforma
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort F: Biliary Tract Cancer (Le
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort G: Pancreatic Cancer (Lenva
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg + 200 mg
NCT03473925 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone30 mg + 200 mg
NCT03473925 · Phase 2 · registry result, not featured evidence · combination
100%1200 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
100%960 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
66.7%480 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm I
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm II
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm III
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm IV
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm IVa
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm V
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm Va
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Biomarker Cohort
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
0%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
0%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
66.7%3 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
57.1%1400 mg + 200 mg
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
87.5%1100 mg + 200 mg
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
73.8%Part 2, Group 1: CRC MMR-proficien
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
93.5%Part 2, Group 2: Pancreatic Cancer
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
75%Part 2, Group 3: NSCLC PD-L1 Low,
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
73.7%Part 2, Group 4a: Refractory / Rel
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
66.7%Part 2, Group 4b: Refractory/Relap
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
—Cohort A: Triple Negative Breast C
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
show 44 more results
—Cohort B: Ovarian Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Gastric Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort D1: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort D2: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence
—Cohort E: Glioblastoma Multiforma
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort F: Biliary Tract Cancer (Le
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort G: Pancreatic Cancer (Lenva
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—100 mg + 200 mg
NCT03473925 · Phase 2 · registry result, not featured evidence · combination
—30 mg + 200 mg
NCT03473925 · Phase 2 · registry result, not featured evidence · combination
—1200 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—960 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—480 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm I
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm II
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm III
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm IV
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm IVa
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm V
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Arm Va
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2a: Biomarker Cohort
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—3 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—1400 mg + 200 mg
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—1100 mg + 200 mg
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2, Group 1: CRC MMR-proficien
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2, Group 2: Pancreatic Cancer
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2, Group 3: NSCLC PD-L1 Low,
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2, Group 4a: Refractory / Rel
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2, Group 4b: Refractory/Relap
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
1.6%100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
51.6%Cohort A: Triple Negative Breast C
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
show 44 more results
61.3%Cohort B: Ovarian Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
57.6%Cohort C: Gastric Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
52.4%Cohort D1: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
40%Cohort D2: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence
29.7%Cohort E: Glioblastoma Multiforma
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
60.8%Cohort F: Biliary Tract Cancer (Le
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
47.6%Cohort G: Pancreatic Cancer (Lenva
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
27.8%100 mg + 200 mg
NCT03473925 · Phase 2 · registry result, not featured evidence · combination
33.3%30 mg + 200 mg
NCT03473925 · Phase 2 · registry result, not featured evidence · combination
16.7%1200 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
33.3%960 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
66.7%480 ug/kg
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
25%Phase 2a: Arm I
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
82.4%Phase 2a: Arm II
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
64.7%Phase 2a: Arm III
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
51.7%Phase 2a: Arm IV
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
71.4%Phase 2a: Arm IVa
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
56.3%Phase 2a: Arm V
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
79.4%Phase 2a: Arm Va
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
69.2%Phase 2a: Biomarker Cohort
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
22.2%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
57.1%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
55.6%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
43.4%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
45.3%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
36.8%5 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
66.7%3 mg weekly
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
45%300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
51%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
40%50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
0%25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—1400 mg + 200 mg
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—1100 mg + 200 mg
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2, Group 1: CRC MMR-proficien
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2, Group 2: Pancreatic Cancer
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2, Group 3: NSCLC PD-L1 Low,
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2, Group 4a: Refractory / Rel
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2, Group 4b: Refractory/Relap
NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination
38.2%100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
35.7%75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
37.5%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
hypertension 51.6%
diarrhoea 45.2%
hypothyroidism 45.2%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
show 35 more results
hypertension 67.7%
diarrhoea 61.3%
decreased appetite 48.4%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 37.4%
nausea 31.3%
asthenia 30.3%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 56.2%
diarrhoea 44.8%
decreased appetite 43.8%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 56.7%
diarrhoea 53.3%
dysphonia 40%
NCT03797326 · Phase 2 · registry result, not featured evidence
hypertension 50.5%
asthenia 28.7%
hypothyroidism 27.7%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 56.9%
diarrhoea 41.2%
fatigue 39.2%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 53.4%
nausea 35.9%
decreased appetite 32%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
100 mg + 200 mg
nausea 29.6%
fatigue 25.9%
pyrexia 22.2%
NCT03473925 · Phase 2 · registry result, not featured evidence · combination
30 mg + 200 mg
fatigue 33.3%
decreased appetite 27.5%
pyrexia 23.5%
NCT03473925 · Phase 2 · registry result, not featured evidence · combination
1200 ug/kg
chills 83.3%
fatigue 66.7%
injection site erythema 66.7%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
960 ug/kg
oedema peripheral 66.7%
anaemia 33.3%
blood bilirubin increased 33.3%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
480 ug/kg
headache 100%
pyrexia 100%
chills 66.7%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
alanine aminotransferase increased 31.3%
cough 31.3%
oedema peripheral 31.3%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 41.2%
nausea 29.4%
oedema peripheral 23.5%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 47.1%
decreased appetite 35.3%
pruritus 23.5%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
nausea 48.3%
fatigue 44.8%
pyrexia 41.4%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 42.9%
pyrexia 42.9%
decreased appetite 35.7%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
pyrexia 43.8%
fatigue 37.5%
nausea 31.3%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 47.1%
anaemia 32.4%
decreased appetite 26.5%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
aspartate aminotransferase increased 38.5%
anaemia 30.8%
fatigue 30.8%
NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
fatigue 66.7%
decreased appetite 55.6%
cough 33.3%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
fatigue 85.7%
cough 42.9%
hypophosphataemia 42.9%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
fatigue 77.8%
musculoskeletal and connective tissue disorders 55.6%
cough 38.9%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
fatigue 47.4%
musculoskeletal and connective tissue disorders 44.7%
decreased appetite 35.5%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
nausea 56.6%
fatigue 54.7%
musculoskeletal and connective tissue disorders 45.3%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
5 mg weekly
fatigue 57.9%
musculoskeletal and connective tissue disorders 44.7%
blood alkaline phosphatase increased 36.8%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
3 mg weekly
decreased appetite 50%
cough 33.3%
diarrhoea 33.3%
NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination
300 mg BID + 200 mg Q3W
fatigue 65%
nausea 55%
vomiting 50%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 50%
back pain 38.9%
diarrhoea 38.9%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 48.4%
nausea 30.1%
cough 26.2%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50 mg BID + 200 mg Q3W
fatigue 65%
arthralgia 45%
nausea 45%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
25 mg BID + 200 mg Q3W
arthralgia 100%
constipation 75%
cough 75%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg
diarrhoea 25.2%
constipation 23.6%
fatigue 23.6%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
75 mg
aspartate aminotransferase increased 21.4%
back pain 21.4%
fatigue 21.4%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
50 mg
fatigue 37.5%
diarrhoea 25%
decreased appetite 18.8%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination

Head and Neck Squamous Cell Carcinoma

Shared mechanism: PD-1 · full Head and Neck Squamous Cell Carcinoma pipeline

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Head and Neck Squamous Cell Carcinomamonoclonal antibody
Partial signal

NCT02105636 · Phase 3 · completed

The trial randomly assigned 361 participants to open-label nivolumab or active comparator therapy, so treatment assignment was not blinded. Its objective primary endpoint, overall survival, was statistically significantly better with nivolumab, but the available record does not report a power calculation; these design limitations support a moderate grade rather than the highest grade.

Next expected readout: November 2026 · NCT02955290 (registry estimate)

Reported efficacy

Overall Survival (OS) (From date of randomization to date of death (Up to approximately 18 months)): Overall Survival (OS) (From date of randomization to date of death (Up to approximately 18 months)): Nivolumab 3mg/kg 7.49 Months (95% CI 5.49 to 9.1) | Investigators Choice 5.06 Months (95% CI 4.04 to 6.05) (met)

Result source: NCT02105636

Pembrolizumab

Marketed by Merck & Co.

Approved in Head and Neck Squamous Cell Carcinomamonoclonal antibody
Partial signal

NCT02358031 · Phase 3 · completed

KEYNOTE-048 was a randomized, open-label, active-controlled Phase 3 in 882 patients with recurrent or metastatic HNSCC. Its primary endpoint, overall survival, is a clinical outcome and was met at a pre-specified interim analysis. An open-label trial is never graded strong under the rubric.

Next expected readout: November 2026 · NCT02955290 (registry estimate)

Reported efficacy

Pembro Combo vs Control: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in All Participants (Up to approximately 47 months); Pembro Combo vs Control: PFS Per RECIST 1.1 by BICR in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 (Up to approximately 47 months); Pembro Combo vs Control: PFS Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥20 (Up to approximately 47 months); Pembro Combo vs Control: Overall Survival (OS) in All Participants (Up to approximately 47 months); Pembro Combo vs Control: OS in Participants With PD-L1 CPS ≥1 (Up to approximately 47 months); Pembro Combo vs Control: OS in Participants With PD-L1 CPS ≥20 (Up to approximately 47 months); Pembro Mono vs Control: PFS Per RECIST 1.1 by BICR in All Participants (Up to approximately 47 months); Pembro Mono vs Control: PFS Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥1 (Up to approximately 47 months); Pembro Mono vs Control: PFS Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥20 (Up to approximately 47 months); Pembro Mono vs Control: OS in All Participants (Up to approximately 47 months); Pembro Mono vs Control: OS in Participants With PD-L1 CPS ≥1 (Up to approximately 47 months); Pembro Mono vs Control: OS in Participants With PD-L1 CPS ≥20 (Up to approximately 47 months): Primary endpoint, overall survival at a pre-specified interim analysis: pembrolizumab plus platinum/fluorouracil vs cetuximab plus platinum/fluorouracil, median 13.0 vs 10.7 months, HR 0.77; pembrolizumab alone vs cetuximab-chemotherapy in PD-L1 CPS >=1, HR 0.65 (95% CI 0.53 to 0.80) (KEYTRUDA label, KEYNOTE-048). (met)

Result source: NCT02358031

Results for Head and Neck Squamous Cell Carcinoma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Nivolumab: 6 of 7 rows · Pembrolizumab: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricNivolumab
Rows use multiple source trials
Pembrolizumab
Rows use multiple source trials
Duration of Response
time to event · months
No placebo or comparator arm
NA months4 mg/kg + 3 mg/kg Q2Wa,b,c
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
show 6 more doses
8.9 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
16.2 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
7.3 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
12.7 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
NA months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
NA months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
NA months5.0 mga,b,c
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
show 6 more doses
NA months5.0 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
NA months3.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
9.26 months2.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
NA months2.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
NA months2.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
NA months0.2 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
ORR
responder rate · % of participants
No placebo or comparator arm
7% (n=14)280 mg PO BIDb,c
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
16 other source trials
0% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
9.1% (n=11)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
9.1% (n=11)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
6.9% (n=29)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
3.4% (n=29)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
3.2% (n=31)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0% (n=31)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
13.3% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
6.7% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
5.9% (n=68)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
6% (n=67)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
6.7% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
16.7% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
13.8% (n=29)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
10.7% (n=28)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
25% (n=4)5.0 mga,b,c
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
show 27 more doses
0% (n=4)5.0 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0% (n=4)5.0 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
25% (n=4)5.0 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0% (n=6)3.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0% (n=6)3.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
16.7% (n=6)3.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0% (n=6)3.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
14.3% (n=7)2.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
14.3% (n=7)2.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
14.3% (n=7)2.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
14.3% (n=7)2.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0% (n=3)1.6 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0% (n=3)1.6 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0% (n=3)1.6 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0% (n=3)1.6 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0% (n=4)0.8 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0% (n=4)0.8 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0% (n=4)0.8 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0% (n=4)0.8 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0% (n=2)0.4 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0% (n=2)0.4 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0% (n=2)0.4 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0% (n=2)0.4 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0% (n=2)0.2 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0% (n=2)0.2 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
50% (n=2)0.2 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0% (n=2)0.2 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
PFS
time to event · months
No placebo or comparator arm
1.8 months4 mg/kg + 3 mg/kg Q2Wa,b,c
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
show 7 more doses
1.8 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
2.8 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
1.9 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
2 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
1.7 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
2.9 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
1.8 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
2.1 months100 mga,b,c
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 3 more doses
3 months100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
2.6 months75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
2.1 months50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Dropout rate
0%280 mg PO BIDd
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
show 11 more results
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%6 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0%6 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
—4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0%4 mg/kg + 3 mg/kg Q3W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0%4 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
25%2 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0%2 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
—1 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone300 mg BID + 200 mg Q3Wd
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
show 28 more results
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—5.0 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone5.0 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—3.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone3.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone2.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—1.6 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1.6 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—0.8 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone0.8 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—0.4 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone0.4 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—0.2 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
57.1%20 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
—12.5 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—280 mg PO BIDd
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
show 11 more results
—140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—6 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
—6 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
—4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
—4 mg/kg + 3 mg/kg Q3W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
—4 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
—2 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
—2 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
—1 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
—300 mg BID + 200 mg Q3Wd
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
show 28 more results
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—5.0 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—5.0 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—3.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—3.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—1.6 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—1.6 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—0.8 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—0.8 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—0.4 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—0.4 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—0.2 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
1.6%100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—20 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
—12.5 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
Serious AEs
14.3%280 mg PO BIDd
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
show 11 more results
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
66.7%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
100%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
50%6 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
54.5%6 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
52.1%4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
50%4 mg/kg + 3 mg/kg Q3W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
10%4 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
33.3%2 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
33.3%2 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
50%1 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
45%300 mg BID + 200 mg Q3Wd
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
show 28 more results
50%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
51%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
40%50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
0%25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50%5.0 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—5.0 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0%3.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—3.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
42.9%2.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
33.3%1.6 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—1.6 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
75%0.8 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—0.8 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
50%0.4 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
—0.4 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0%0.2 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
14.3%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
66.7%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
100%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
38.2%100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
35.7%75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
37.5%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
14.3%20 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
—12.5 mg/kg
NCT03236935 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
280 mg PO BIDd
aspartate aminotransferase increased 14.3%
cough 14.3%
fatigue 14.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
show 11 more results
140 mg / 280 mg
anemia 66.7%
back pain 66.7%
diarrhea 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO BID
lipase increased 66.7%
alkaline phosphatase increased 33.3%
anorexia 33.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO daily
hepatobiliary disorders - other, specify 100%
abdominal pain 66.7%
back pain 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
6 mg/kg + 3 mg/kg Q2W
fatigue 100%
dehydration 83.3%
periorbital oedema 83.3%
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
6 mg/kg Q2W
aspartate aminotransferase increased 60%
blood creatine phosphokinase increased 40%
fatigue 40%
NCT02526017 · Phase 1 · registry result, not featured evidence
4 mg/kg + 3 mg/kg Q2W
fatigue 55.8%
blood creatine phosphokinase increased 47.2%
periorbital oedema 46%
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
4 mg/kg + 3 mg/kg Q3W
candida infection 40%
dizziness 40%
fall 40%
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
4 mg/kg Q2W
abdominal pain 45.5%
aspartate aminotransferase increased 45.5%
fatigue 45.5%
NCT02526017 · Phase 1 · registry result, not featured evidence
2 mg/kg + 3 mg/kg Q2W
amylase increased 33.3%
arthralgia 33.3%
aspartate aminotransferase increased 33.3%
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
2 mg/kg Q2W
fatigue 66.7%
blood alkaline phosphatase increased 33.3%
blood bilirubin increased 33.3%
NCT02526017 · Phase 1 · registry result, not featured evidence
1 mg/kg + 3 mg/kg Q2W
anaemia 50%
amylase increased 25%
aspartate aminotransferase increased 25%
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
300 mg BID + 200 mg Q3Wd
fatigue 65%
nausea 55%
vomiting 50%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
show 19 more results
100 mg BID + 200 mg Q3W
fatigue 50%
back pain 38.9%
diarrhoea 38.9%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 48.4%
nausea 30.1%
cough 26.2%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50 mg BID + 200 mg Q3W
fatigue 65%
arthralgia 45%
nausea 45%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
25 mg BID + 200 mg Q3W
arthralgia 100%
constipation 75%
cough 75%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
5.0 mg
pain in extremity 50%
anaemia 33.3%
arthralgia 33.3%
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
3.5 mg
diarrhoea 50%
fatigue 50%
chills 33.3%
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
2.5 mg
fatigue 71.4%
constipation 57.1%
cough 42.9%
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
1.6 mg
constipation 33.3%
device malfunction 33.3%
fatigue 33.3%
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0.8 mg
fatigue 75%
abdominal distension 25%
abdominal pain 25%
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0.4 mg
anaemia 50%
balance disorder 50%
constipation 50%
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
0.2 mg
cough 50%
oesophagitis 50%
arthralgia 25%
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
280 mg PO BID
aspartate aminotransferase increased 14.3%
cough 14.3%
fatigue 14.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg / 280 mg
anemia 66.7%
back pain 66.7%
diarrhea 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO BID
lipase increased 66.7%
alkaline phosphatase increased 33.3%
anorexia 33.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO daily
hepatobiliary disorders - other, specify 100%
abdominal pain 66.7%
back pain 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
100 mg
diarrhoea 25.2%
constipation 23.6%
fatigue 23.6%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
75 mg
aspartate aminotransferase increased 21.4%
back pain 21.4%
fatigue 21.4%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
50 mg
fatigue 37.5%
diarrhoea 25%
decreased appetite 18.8%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
20 mg/kg
hypertension 28.6%
anemia 14.3%
arthralgia 14.3%
NCT03236935 · Phase 1 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation context differs: registered conditions differ.
  3. cThe assessment timepoint is not available for both results.
  4. dPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Nivolumab

Overall Survival 12.3 months4 mg/kg + 3 mg/kg Q2W
time to event · months
No placebo or comparator arm
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
show 7 more results
4.7 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
6.4 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
5.6 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
13.9 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
NA months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
8.1 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
5.3 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
Overall Survival Rate at 12 51.1% (n=30) @ 52wk4 mg/kg + 3 mg/kg Q2W
responder rate · % of participants
No placebo or comparator arm
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
show 7 more results
29.2% (n=31) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
42.5% (n=30) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
27.2% (n=68) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
52.9% (n=31) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
77.8% (n=30) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
35% (n=30) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
36.4% (n=11) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination

Pembrolizumab

Time to Response 5.39 months5.0 mg
time to event · months
No placebo or comparator arm
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
show 6 more results
5.39 months5.0 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
1.15 months3.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
1.38 months2.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
3.45 months2.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
1.38 months2.5 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
1.41 months0.2 mg
NCT04879849 · Phase 1 · registry result, not featured evidence · combination
Complete 0% (n=10)100 mg
responder rate · % of participants
No placebo or comparator arm
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 3 more results
1.7% (n=118)100 mg
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0% (n=13)75 mg
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0% (n=10)50 mg
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Partial 0% (n=10)100 mg
responder rate · % of participants
No placebo or comparator arm
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 3 more results
9.3% (n=118)100 mg
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
7.7% (n=13)75 mg
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
10% (n=10)50 mg
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination

Renal Cell Carcinoma

Shared mechanism: PD-1 · full Renal Cell Carcinoma pipeline

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Renal Cell Carcinomamonoclonal antibody
Partial signal

NCT02231749 · Phase 3 · completed

The trial was randomized and actively controlled, with 550 patients receiving nivolumab plus ipilimumab and 546 receiving sunitinib, but it was open-label. Its objective clinical endpoints were favorable for the nivolumab combination, with statistically significant comparisons reported for response rate, overall survival, and progression-free survival; however, the registry does not document the power calculation needed to establish adequate powering, so this is moderate evidence rather than strong evidence.

Next expected readout: December 2026 · NCT05263050 (registry estimate)

Reported efficacy

Overall Survival (OS) at Primary Endpoint (Randomization until 398 deaths, up to May 2015 (approximately 30 months)): Overall Survival (OS) at Primary Endpoint (Randomization until 398 deaths, up to May 2015 (approximately 30 months)): Nivolumab 25 months | Everolimus 19.55 months (95% CI 17.64 to 23.06) (met)

Result source: NCT01668784

Pembrolizumab

Marketed by Merck & Co.

Approved in Renal Cell Carcinomamonoclonal antibody
Partial signal

NCT02853331 · Phase 3 · completed

The trial randomly assigned 861 participants to open-label pembrolizumab plus axitinib or active-controlled sunitinib monotherapy, with progression assessed by blinded independent central imaging review. Both prespecified primary endpoints favored the combination: progression-free survival was significantly improved (HR 0.69, p=0.00012) and overall survival was significantly improved (HR 0.53, p=0.00005), but the open-label design limits the evidence strength.

Next expected readout: December 2026 · NCT05319015 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) by Independent Imaging Review (IIR) (From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)): Progression-free Survival (PFS) by Independent Imaging Review (IIR) (From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)): Lenvatinib 18 mg Plus Everolimus 5 mg 14.7 months (95% CI 11.1 to 16.7) | Lenvatinib 20 mg Plus Pembrolizumab 200 mg 23.9 months (95% CI 20.8 to 27.7) | Sunitinib 50 mg 9.2 months (95% CI 6 to 11) (met)

Result source: NCT02811861

Results for Renal Cell Carcinoma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Nivolumab: 7 of 8 rows · Pembrolizumab: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricNivolumab
Rows use multiple source trials
Pembrolizumab
Rows use multiple source trials
Duration of Response
time to event · months
No placebo or comparator arm
NA months30 mga,b,c,d
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more doses
7.38 months*30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 32 weeks as posted
20.63 months*30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 89.4 weeks as posted
12.4 months100 mga,b,c,d
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 2 more doses
NA months75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
NA months50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
ORR
event count · % of participants
No placebo or comparator arm
14.9% (n=429)*0.006 mg/kg q3w + 360 mg q3wa,b,c,d
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 64 Participants as posted
show 1 more dose
17.6% (n=17)*
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
20% (n=5)*3.2/4 mga,b,c,d
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
show 19 more doses
20% (n=5)*3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
6.3% (n=95)*1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 6 Participants as posted
10.7% (n=28)*1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
39.6% (n=48)*1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 19 Participants as posted
0% (n=5)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted
46.7% (n=15)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
0% (n=6)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
16.7% (n=6)*0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
20% (n=5)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
35.7% (n=14)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted
100% (n=1)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
0% (n=5)*0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
0% (n=6)*0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted
33.3% (n=3)*0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
20% (n=5)*0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
0% (n=4)*0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
0% (n=5)*0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted
25% (n=4)*0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
0% (n=4)*0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted
ORR
responder rate · % of participants
No placebo or comparator arm
7% (n=14)280 mg PO BIDe,d
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
16 other source trials
0% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
9.1% (n=11)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
9.1% (n=11)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
6.9% (n=29)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
3.4% (n=29)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
3.2% (n=31)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0% (n=31)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
13.3% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
6.7% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
5.9% (n=68)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
6% (n=67)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
6.7% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
16.7% (n=30)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
13.8% (n=29)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
10.7% (n=28)4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
7% (n=14)280 mg PO BIDe,d
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
4 other source trials
0% (n=10)100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
10% (n=10)50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
7.7% (n=13)75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
11% (n=118)100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
PFS
time to event · months
No placebo or comparator arm
18.37 months*30 mga,b,c,d
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 79.6 weeks as posted
show 2 more doses
2.33 months*30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 10.1 weeks as posted
3.37 months*30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 14.6 weeks as posted
2.1 months100 mga,b,c,d
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 3 more doses
3 months100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
2.6 months75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
2.1 months50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Dropout rate
100%40 mgf
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
show 47 more results
100%30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
97.5%30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
100%20 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
0%0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
20%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
17.2%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
10.5%Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
100%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
99.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
96.5%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
85.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
0%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%6 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0%6 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
—4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0%4 mg/kg + 3 mg/kg Q3W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0%4 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
25%2 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
0%2 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
—1 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone300 mg BID + 200 mg Q3Wf
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
show 35 more results
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
99.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
96.5%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
85.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
0%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
—40 mgf
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
show 47 more results
—30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
—30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
—20 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
—0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—6 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
—6 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
—4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
—4 mg/kg + 3 mg/kg Q3W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
—4 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
—2 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
—2 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
—1 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
—300 mg BID + 200 mg Q3Wf
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
show 35 more results
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
1.6%100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
57.1%40 mgf
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
show 47 more results
85.7%30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
49.4%30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
33.3%20 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
66.7%0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
50%0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
36%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
44.7%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
60%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
62.5%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
42.1%Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
40%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
60%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
51.3%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
47.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
56.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
55.6%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
66.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
66.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
16.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
57.1%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
20%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
40%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
0%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
75%0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
14.3%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
66.7%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
100%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
50%6 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
54.5%6 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
52.1%4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
50%4 mg/kg + 3 mg/kg Q3W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
10%4 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
33.3%2 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
33.3%2 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence
50%1 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
45%300 mg BID + 200 mg Q3Wf
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
show 35 more results
50%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
51%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
40%50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
0%25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
40%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
60%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
51.3%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
47.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
56.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
55.6%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
66.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
66.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
16.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
57.1%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
20%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
40%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
0%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
75%0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
14.3%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
66.7%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
100%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
38.2%100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
35.7%75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
37.5%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
40 mgf
anaemia 57.1%
decreased appetite 57.1%
contusion 42.9%
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
show 45 more results
30 mg
fatigue 71.4%
weight decreased 71.4%
anaemia 57.1%
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
30 mg
fatigue 65.8%
nausea 55.7%
diarrhoea 53.2%
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
20 mg
diarrhoea 66.7%
dyspnoea 66.7%
fatigue 66.7%
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
0.009 mg/kg q3w + 360 mg q3w
pyrexia 100%
rash 100%
chills 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 240 mg q2w
arthralgia 100%
fatigue 100%
headache 100%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q2w + 240 mg q2w
chills 100%
pyrexia 100%
back pain 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 360 mg q3w
fatigue 76%
chills 64%
cough 60%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 360 mg q3w
fatigue 50.6%
pyrexia 47.9%
nausea 40.1%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.003 mg/kg q2w + 240 mg q2w
chills 100%
nasal congestion 100%
arthralgia 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 90%
diarrhoea 80%
nausea 80%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
diarrhoea 75%
influenza like illness 75%
pruritus 75%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
decreased appetite 100%
fatigue 100%
influenza like illness 100%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 78.9%
influenza like illness 68.4%
nausea 57.9%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
3.2/4 mg
anaemia 80%
decreased appetite 80%
fatigue 80%
NCT02009449 · Phase 1 · registry result, not featured evidence
3.2/4 mg
fatigue 100%
anaemia 80%
headache 60%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
1.6/2 mg
anaemia 75.2%
fatigue 59%
thrombocytopenia 59%
NCT02009449 · Phase 1 · registry result, not featured evidence
1.6/2 mg
fatigue 85.3%
anaemia 76.5%
thrombocytopenia 58.8%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
1.6/2 mg
anaemia 68.4%
fatigue 59.6%
cough 42.1%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
constipation 66.7%
decreased appetite 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.8/1 mg
fatigue 88.9%
nausea 83.3%
anaemia 77.8%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
thrombocytopenia 66.7%
fatigue 50%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
fatigue 66.7%
thrombocytopenia 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
fatigue 100%
decreased appetite 66.7%
lipase increased 50%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
fatigue 85.7%
thrombocytopenia 71.4%
anaemia 57.1%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
activated partial thromboplastin time prolonged 100%
alanine aminotransferase increased 100%
anaemia 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 100%
fatigue 100%
thrombocytopenia 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
anaemia 83.3%
fatigue 83.3%
nausea 83.3%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.4/0.5 mg
anaemia 100%
dyspnoea 66.7%
fatigue 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
thrombocytopenia 100%
fatigue 66.7%
anaemia 33.3%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
fatigue 100%
anaemia 80%
hypokalaemia 60%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.2/0.25 mg
anaemia 50%
fatigue 50%
injection site erythema 50%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.2/0.25 mg
asthenia 100%
neutropenia 100%
spermatic cord disorder 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.08/0.1 mg
injection site erythema 75%
abdominal distension 50%
abdominal pain 50%
NCT02009449 · Phase 1 · registry result, not featured evidence
280 mg PO BID
aspartate aminotransferase increased 14.3%
cough 14.3%
fatigue 14.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg / 280 mg
anemia 66.7%
back pain 66.7%
diarrhea 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO BID
lipase increased 66.7%
alkaline phosphatase increased 33.3%
anorexia 33.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO daily
hepatobiliary disorders - other, specify 100%
abdominal pain 66.7%
back pain 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
6 mg/kg + 3 mg/kg Q2W
fatigue 100%
dehydration 83.3%
periorbital oedema 83.3%
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
6 mg/kg Q2W
aspartate aminotransferase increased 60%
blood creatine phosphokinase increased 40%
fatigue 40%
NCT02526017 · Phase 1 · registry result, not featured evidence
4 mg/kg + 3 mg/kg Q2W
fatigue 55.8%
blood creatine phosphokinase increased 47.2%
periorbital oedema 46%
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
4 mg/kg + 3 mg/kg Q3W
candida infection 40%
dizziness 40%
fall 40%
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
4 mg/kg Q2W
abdominal pain 45.5%
aspartate aminotransferase increased 45.5%
fatigue 45.5%
NCT02526017 · Phase 1 · registry result, not featured evidence
2 mg/kg + 3 mg/kg Q2W
amylase increased 33.3%
arthralgia 33.3%
aspartate aminotransferase increased 33.3%
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
2 mg/kg Q2W
fatigue 66.7%
blood alkaline phosphatase increased 33.3%
blood bilirubin increased 33.3%
NCT02526017 · Phase 1 · registry result, not featured evidence
1 mg/kg + 3 mg/kg Q2W
anaemia 50%
amylase increased 25%
aspartate aminotransferase increased 25%
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
300 mg BID + 200 mg Q3Wf
fatigue 65%
nausea 55%
vomiting 50%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
show 31 more results
100 mg BID + 200 mg Q3W
fatigue 50%
back pain 38.9%
diarrhoea 38.9%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 48.4%
nausea 30.1%
cough 26.2%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50 mg BID + 200 mg Q3W
fatigue 65%
arthralgia 45%
nausea 45%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
25 mg BID + 200 mg Q3W
arthralgia 100%
constipation 75%
cough 75%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
3.2/4 mg
anaemia 80%
decreased appetite 80%
fatigue 80%
NCT02009449 · Phase 1 · registry result, not featured evidence
3.2/4 mg
fatigue 100%
anaemia 80%
headache 60%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
1.6/2 mg
anaemia 75.2%
fatigue 59%
thrombocytopenia 59%
NCT02009449 · Phase 1 · registry result, not featured evidence
1.6/2 mg
fatigue 85.3%
anaemia 76.5%
thrombocytopenia 58.8%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
1.6/2 mg
anaemia 68.4%
fatigue 59.6%
cough 42.1%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
constipation 66.7%
decreased appetite 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.8/1 mg
fatigue 88.9%
nausea 83.3%
anaemia 77.8%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
thrombocytopenia 66.7%
fatigue 50%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
fatigue 66.7%
thrombocytopenia 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
fatigue 100%
decreased appetite 66.7%
lipase increased 50%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
fatigue 85.7%
thrombocytopenia 71.4%
anaemia 57.1%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
activated partial thromboplastin time prolonged 100%
alanine aminotransferase increased 100%
anaemia 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 100%
fatigue 100%
thrombocytopenia 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
anaemia 83.3%
fatigue 83.3%
nausea 83.3%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.4/0.5 mg
anaemia 100%
dyspnoea 66.7%
fatigue 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
thrombocytopenia 100%
fatigue 66.7%
anaemia 33.3%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
fatigue 100%
anaemia 80%
hypokalaemia 60%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.2/0.25 mg
anaemia 50%
fatigue 50%
injection site erythema 50%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.2/0.25 mg
asthenia 100%
neutropenia 100%
spermatic cord disorder 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.08/0.1 mg
injection site erythema 75%
abdominal distension 50%
abdominal pain 50%
NCT02009449 · Phase 1 · registry result, not featured evidence
280 mg PO BID
aspartate aminotransferase increased 14.3%
cough 14.3%
fatigue 14.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg / 280 mg
anemia 66.7%
back pain 66.7%
diarrhea 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO BID
lipase increased 66.7%
alkaline phosphatase increased 33.3%
anorexia 33.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO daily
hepatobiliary disorders - other, specify 100%
abdominal pain 66.7%
back pain 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
100 mg
diarrhoea 25.2%
constipation 23.6%
fatigue 23.6%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
75 mg
aspartate aminotransferase increased 21.4%
back pain 21.4%
fatigue 21.4%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
50 mg
fatigue 37.5%
diarrhoea 25%
decreased appetite 18.8%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 1 versus Phase 1/2.
  3. cPopulation context differs: registered conditions differ.
  4. dThe assessment timepoint is not available for both results.
  5. ePopulation comparability has not been reviewed for both studies.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Nivolumab

ORR 56.6% (n=53)30 mg
absolute value · percentage points
No placebo or comparator arm
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
22.7% (n=22)30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
16.7% (n=6)30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
Disease Control 84.9% (n=53)30 mg
absolute value · percentage points
No placebo or comparator arm
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
68.2% (n=22)30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
66.7% (n=6)30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
Overall Survival 12.3 months4 mg/kg + 3 mg/kg Q2W
time to event · months
No placebo or comparator arm
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
show 7 more results
4.7 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
6.4 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
5.6 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
13.9 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
NA months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
8.1 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
5.3 months4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
Overall Survival Rate at 12 51.1% (n=30) @ 52wk4 mg/kg + 3 mg/kg Q2W
responder rate · % of participants
No placebo or comparator arm
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
show 7 more results
29.2% (n=31) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
42.5% (n=30) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
27.2% (n=68) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
52.9% (n=31) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
77.8% (n=30) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
35% (n=30) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination
36.4% (n=11) @ 52wk4 mg/kg + 3 mg/kg Q2W
NCT02526017 · Phase 1 · registry result, not featured evidence · combination

Pembrolizumab

Complete 0% (n=10)100 mg
responder rate · % of participants
No placebo or comparator arm
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 3 more results
1.7% (n=118)100 mg
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0% (n=13)75 mg
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0% (n=10)50 mg
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Partial 0% (n=10)100 mg
responder rate · % of participants
No placebo or comparator arm
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 3 more results
9.3% (n=118)100 mg
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
7.7% (n=13)75 mg
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
10% (n=10)50 mg
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination

Metastatic Colorectal Cancer

Shared mechanism: PD-1 · full Metastatic Colorectal Cancer pipeline

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Metastatic Colorectal Cancermonoclonal antibody
Weak signal

NCT02060188 · Phase 2 · completed

The study was non-randomized, unblinded, and had no comparator arm; its 385 participants were distributed across multiple treatment cohorts, including small cohorts. The primary endpoint was investigator-assessed tumor response, and although results were posted, there was no controlled primary comparison to determine whether nivolumab improved outcomes.

Next expected readout: December 2027 · NCT04017650 (registry estimate)

No aligned efficacy figure on record for this race.

Pembrolizumab

Marketed by Merck & Co.

Approved in Metastatic Colorectal Cancermonoclonal antibody
Weak signal

NCT02460198 · Phase 2 · completed

The study treated 124 participants with pembrolizumab in a non-randomized, open-label, single-group design without a placebo or active comparator. Although the primary endpoint was an objective tumor response measure assessed by central imaging, the study had no formal between-group comparison and therefore provides limited evidence of pembrolizumab’s comparative benefit.

Next expected readout: December 2026 · NCT04140526 (registry estimate)

Reported efficacy

Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48) (not_applicable)

Result source: NCT02460198

Results for Metastatic Colorectal Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Nivolumab: registry results are on file for Metastatic Colorectal Cancer, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Pembrolizumab
Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48) NCT02460198 · Phase 2 · design grade: weak · reviewed ClinicalTrials.gov result

Esophageal Squamous Cell Carcinoma

Shared mechanism: PD-1 · full Esophageal Squamous Cell Carcinoma pipeline

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Esophageal Squamous Cell Carcinomamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: February 2027 · NCT06047379 (registry estimate)

No aligned efficacy figure on record for this race.

Pembrolizumab

Marketed by Merck & Co.

Approved in Esophageal Squamous Cell Carcinomamonoclonal antibody
Partial signal

NCT03189719 · Phase 3 · completed

KEYNOTE-590 was a randomized, double-blind, placebo-controlled Phase 3 in 749 patients with advanced esophageal or gastroesophageal junction carcinoma. Its primary endpoints, overall and progression-free survival, are clinical outcomes and were met. The benefit was concentrated in PD-L1 CPS >=1 tumours, and the sources read give no power calculation, so the grade is moderate.

Next expected readout: December 2026 · NCT06907602 (registry estimate)

Reported efficacy

Overall Survival (OS) in Participants With Esophageal Squamous Cell Carcinoma (ESCC) Whose Tumors Are Programmed Cell Death-Ligand 1 (PD-L1) Biomarker-Positive (Combined Positive Score [CPS] ≥10) (Up to approximately 34 months); OS in Participants With ESCC (Up to approximately 34 months); OS in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10) (Up to approximately 34 months); OS in All Participants (Up to approximately 34 months); Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) As Assessed By Investigator in Participants With ESCC (Up to approximately 34 months); PFS Per RECIST 1.1 As Assessed By Investigator in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10) (Up to approximately 34 months); PFS Per RECIST 1.1 As Assessed By Investigator in All Participants (Up to approximately 34 months): Primary endpoints, overall survival and progression-free survival: pembrolizumab plus cisplatin/fluorouracil improved both vs placebo plus chemotherapy; the label restricts use to PD-L1 CPS >=1, as an exploratory CPS <1 analysis showed OS HR 0.96 (KEYTRUDA label, KEYNOTE-590). (met)

Result source: NCT03189719

Results for Esophageal Squamous Cell Carcinoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Nivolumab: registry results are on file for Esophageal Squamous Cell Carcinoma, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Pembrolizumab
Primary endpoints, overall survival and progression-free survival: pembrolizumab plus cisplatin/fluorouracil improved both vs placebo plus chemotherapy; the label restricts use to PD-L1 CPS >=1, as an exploratory CPS <1 analysis showed OS HR 0.96 (KEYTRUDA label, KEYNOTE-590). NCT03189719 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
Overall survival, pembrolizumab vs investigator's-choice chemotherapy: HR 0.70 (95% CI 0.52 to 0.94) in PD-L1 CPS >=10, HR 0.77 (0.63 to 0.96) in ESCC, HR 0.89 (0.75 to 1.05) in all randomized patients; the label approval is for ESCC with CPS >=10 (KEYTRUDA label, KEYNOTE-181). NCT02564263 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Nivolumab's landscape · Pembrolizumab's landscape